



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 259/06, 237/22, A61K 31/16, 31/165		A1	(11) International Publication Number: WO 99/67201
			(43) International Publication Date: 29 December 1999 (29.12.99)
(21) International Application Number: PCT/GB99/01954		Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).	
(22) International Filing Date: 22 June 1999 (22.06.99)		(74) Agent: WEST, Vivien; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).	
(30) Priority Data: 9813451.3 22 June 1998 (22.06.98) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): FALLER, Andrew [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). MacPHERSON, David, Timothy [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). MILNER, Peter, Henry [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). MISTRY, Jayshree [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). WARD, John, Gerard [GB/GB]; SmithKline Beecham			
(54) Title: HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE			
$ \begin{array}{c} \text{O} \quad \text{R}^1 \quad \text{O} \\ \parallel \quad \quad \parallel \\ \text{HONH}-\text{C}-\text{C}-\text{C}-\text{N}-\text{C}-\text{C}-\text{NH}(\text{O})_n\text{R}^3 \\ \quad \quad \quad \quad \\ \text{OR} \quad \text{O} \quad \text{R}^2 \end{array} \quad (1) $			
(57) Abstract			
Compounds of formula (I) wherein: R is methyl substituted by one to three groups selected from alkyl, aryl, alkenyl, and alkynyl; n is 0 or 1; R ¹ is arylmethyl or heterocyclylmethyl; R ² is alkyl, alkenyl, cycloalkyl or cycloalkenyl; and R ³ is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated by s-CD23.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE

This invention relates to novel inhibitors of the formation of soluble human CD23 and their use in the treatment of conditions associated with excess
5 production of soluble CD23 (s-CD23) such as autoimmune disease and allergy. The compounds of the invention are also inhibitors of the release of tumour necrosis factor (TNF).

CD23 (the low affinity IgE receptor FcεRII, Blast 2), is a 45 kDa type II integral protein expressed on the surface of a variety of mature cells, including B
10 and T lymphocytes, macrophages, natural killer cells, Langerhans cells, monocytes and platelets (Delespesse *et al*, *Adv Immunol*, 49 [1991] 149-191). There is also a CD23-like molecule on eosinophils (Grangette *et al*, *J Immunol*, 143 [1989] 3580-3588). CD23 has been implicated in the regulation of the immune response (Delespesse *et al*, *Immunol Rev*, 125 [1992] 77-97). Human
15 CD23 exists as two differentially regulated isoforms, a and b, which differ only in the amino acids at the intracellular N-terminus (Yokota *et al*, *Cell*, 55 [1988] 611-618). In man the constitutive a isoform is found only on B-lymphocytes, whereas type b, inducible by IL4, is found on all cells capable of expressing CD23.

Intact, cell bound CD23 (i-CD23) is known to undergo cleavage from the
20 cell surface leading to the formation of a number of well-defined soluble fragments (s-CD23), which are produced as a result of a complex sequence of proteolytic events, the mechanism of which is still poorly understood (Bourget *et al* *J Biol Chem*, 269 [1994] 6927-6930). Although not yet proven, it is postulated that the major soluble fragments (Mr 37, 33, 29 and 25 kDa) of these proteolytic
25 events, all of which retain the C-terminal lectin domain common to i-CD23, occur sequentially via initial formation of the 37 kDa fragment (Letellier *et al*, *J Exp Med*, 172 [1990] 693-700). An alternative intracellular cleavage pathway leads to a stable 16 kDa fragment differing in the C-terminal domain from i-CD23 (Grenier-Brossette *et al*, *Eur J Immunol*, 22 [1992] 1573-1577).

30 Several activities have been ascribed to membrane bound i-CD23 in humans, all of which have been shown to play a role in IgE regulation. Particular activities include: a) antigen presentation, b) IgE mediated eosinophil cytotoxicity, c) B cell homing to germinal centres of lymph nodes and spleen, and

d) downregulation of IgE synthesis (Delespesse *et al*, *Adv Immunol*, 49, [1991] 149-191). The three higher molecular weight soluble CD23 fragments (Mr 37, 33 and 29 kDa) have multifunctional cytokine properties which appear to play a major role in IgE production. Thus, the excessive formation of s-CD23 has been implicated in the overproduction of IgE, the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjunctivitis, eczema, atopic dermatitis and anaphylaxis (Sutton and Gould, *Nature*, 366, [1993] 421-428). Other biological activities attributed to s-CD23 include the stimulation of B cell growth and the induction of the release of mediators from monocytes. Thus, elevated levels of s-CD23 have been observed in the serum of patients having B-chronic lymphocytic leukaemia (Sarfati *et al*, *Blood*, 71 [1988] 94-98) and in the synovial fluids of patients with rheumatoid arthritis (Chomarat *et al*, *Arthritis and Rheumatism*, 36 [1993] 234-242). That there is a role for CD23 in inflammation is suggested by a number of sources. First, sCD23 has been reported to bind to extracellular receptors which when activated are involved in cell-mediated events of inflammation. Thus, sCD23 is reported to directly activate monocyte TNF, IL-1, and IL-6 release (Armant *et al*, vol 180, *J.Exp. Med.*, 1005-1011 (1994)). CD23 has been reported to interact with the B2-integrin adhesion molecules, CD11b and CD11c on monocyte/macrophage (S. Lecoanet-Henchoz *et al*, *Immunity*, vol 3; 119-125 (1995)) which trigger NO₂⁻, hydrogen peroxide and cytokine (IL-1, IL-6, and TNF) release. Finally, IL-4 or IFN induce the expression of CD23 and its release as sCD23 by human monocytes. Ligation of the membrane bound CD23 receptor with IgE/anti-IgE immune complexes or anti CD23 mAb activates cAMP and IL-6 production and thromboxane B2 formation, demonstrating a receptor-mediated role of CD23 in inflammation.


Because of these various properties of CD23, compounds which inhibit the formation of s-CD23 should have twofold actions of a) enhancing negative feedback inhibition of IgE synthesis by maintaining levels of i-CD23 on the surface of B cells, and b) inhibiting the immunostimulatory cytokine activities of higher molecular weight soluble fragments (Mr 37, 33 and 29 kDa) of s-CD23. In addition, inhibition of CD23 cleavage should mitigate sCD23-induced monocyte activation and mediator formation, thereby reducing the inflammatory response.

TNF α is a pro-inflammatory cytokine which is released from stimulated cells by specific cleavage of a 76-amino acid signal sequence in the inactive precursor to generate the mature form. The cleavage of TNF α has been reported to be carried out by a metalloprotease (Gearing, A.J.H. et al, (1994) Nature 370, 555-557; McGeehan, G.M. et al, (1994) Nature 370, 558-561; Mohler, K.M. et al, (1994) Nature 370, 218-220). Compounds reported to inhibit the cleavage of TNF α by the TNF processing enzyme can be broadly described as matrix metalloprotease inhibitors, particularly of the hydroxamic acid class.

TNF α is induced in a variety of cell types in response to bacteria, endotoxin, various viruses and parasites, so that one physiological function ascribed to TNF α is a contribution to the inflammatory response to acute infection by bacteria, parasites, etc (Dinarello, C.A. (1992) Immunol. 4, 133-145). Overproduction of TNF α has been implicated in disease states such as rheumatoid arthritis, septic shock, Crohn's disease and cachexia (Dinarello, 1992). Inhibition of processing of TNF α to the mature, active form would therefore be beneficial in the treatment of these inflammatory disorders. TNF α may also contribute to the destruction of tissue in autoimmune disease although it is not a initiating factor in these diseases. Confirming the importance of TNF α in rheumatoid arthritis, TNF α antibodies have been shown to reduce the severity of disease in short term studies in rheumatoid arthritis models (Elliott, M.J., et al (1993) Arthrit. Rheum. 12, 1681-1690; Elliott et al (1994) Lancet 344, 1125-1127).

International Patent Application No. WO 96/02240 (Smithkline Beecham plc) discloses that compounds which inhibit the action of matrix metalloproteases (eg collagenase, stromelysin and gelatinase) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems.

UK Patent Application No. 9601041.8 (Smithkline Beecham plc) discloses that certain compounds of formula (I) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems:



(I)

According to the present invention, there is provided a compound of formula (I) above, wherein:

n is 0 or 1;

R is methyl substituted by one to three groups selected from alkyl, aryl, alkenyl, and alkynyl;

R¹ is arylmethyl or heterocyclylmethyl;

R² is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and

R³ is hydrogen, alkyl, alkenyl, alkynyl or aryl.

Alkyl, alkenyl and alkynyl groups referred to herein include straight and branched groups containing up to six carbon atoms and are optionally substituted by one or more groups selected from the group consisting of aryl, heterocyclyl, (C₁₋₆)alkylthio, (C₁₋₆)alkoxy, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, amino, mono- or di-(C₁₋₆)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy, and halogen.

Cycloalkyl and cycloalkenyl groups referred to herein include groups having between three and eight ring carbon atoms and are optionally substituted as described hereinabove for alkyl, alkenyl and alkynyl groups.

When used herein, the term "aryl" means single and fused rings suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring, which rings, may each be unsubstituted or substituted by, for example, up to three substituents. A fused ring system may include aliphatic rings and need include only one aromatic ring.

Suitable aryl groups include phenyl and naphthyl such as 1-naphthyl or 2-naphthyl.

Suitably any aryl group, including phenyl and naphthyl, may be optionally substituted by up to five, preferably up to three substituents. Suitable substituents include halogen, (C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, hydroxy, nitro, cyano, azido, amino, mono- and di-N-(C₁₋₆)alkylamino, acylamino, arylcarbonylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxycarbonyl,

ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl (C₁₋₆)alkyl. In addition, two adjacent ring carbon atoms may be linked by a (C₃₋₅)alkylene chain, to form a carbocyclic ring.

5 When used herein the terms "heterocyclyl" and "heterocyclic" suitably include, unless otherwise defined, aromatic and non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring, each of which is selected from oxygen, nitrogen and sulphur, which rings, may be unsubstituted or substituted by, for example, up to three substituents. Each heterocyclic ring
10 suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

Preferably a substituent for a heterocyclyl group is selected from halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, amino, mono- and di-*N*-(C₁₋₆)alkyl-amino, acylamino, carboxy
15 salts, carboxy esters, carbamoyl, mono- and di-*N*-(C₁₋₆)alkylcarbonyl, aryloxycarbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and
20 heterocyclyl(C₁₋₆)alkyl.

In a particular aspect of the invention, R is allyl, propyl, ethyl or isopropyl, and/or R¹ is 1- or 2-naphthylmethyl; and/or R² is t-butyl; and/or R³ is hydrogen or methyl. In a further aspect of the invention, , each of R to R³ is selected from the group consisting of the values ascribed to it in the Examples
25 hereinbelow. Preferably, the compound of formula (I) of the invention is selected from the group consisting of the compounds described in the Examples hereinbelow.

According to a further aspect, the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or
30 prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated.

In a further aspect the invention provides a method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated, which method comprises the administration of a compound of formula (I), to a human or non-
5 human mammal in need thereof.

The invention also provides a pharmaceutical composition for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated which comprises a compound of formula (I) and optionally a pharmaceutically
10 acceptable carrier therefor.

According to a further aspect, the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or prophylaxis of conditions mediated by TNF, including, but not limited to, inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute
15 phase response, cachexia and anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.

In a further aspect the invention provides a method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound of formula (I), to a human or non-human mammal
20 in need thereof.

The invention also provides a pharmaceutical composition for the treatment or prophylaxis of conditions mediated by TNF, which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier
therefor.

25 Particular inflammatory disorders include CNS disorders such as Alzheimers disease, multiple sclerosis, and multi-infarct dementia, as well as the inflammation mediated sequelae of stroke and head trauma.

It is to be understood that the pharmaceutically acceptable salts, solvates and other pharmaceutically acceptable derivatives of the compound of formula (I)
30 are also included in the present invention.

Salts of compounds of formula (I) include for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, hydroiodides, p-toluenesulphonates, phosphates, sulphates, acetates,

trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartarates and benzoates.


Salts may also be formed with bases. Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as sodium or potassium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

It has surprisingly been found that the compounds of the present invention are potent and selective inhibitors of CD23 processing and TNF release, whilst exhibiting reduced collagenase inhibitory activity in comparison with the above-mentioned compounds of the prior art. The compounds of the invention also exhibit advantageous in-vivo absorption properties via the oral route.

The compounds of the invention may be prepared by use of any appropriate conventional method, for example by analogy with the methods disclosed in patent publication WO97/02239 (BBL).


15 Accordingly, a further aspect of the invention provides a process for preparing a compound of formula (I) as defined hereinabove, which process comprises:

(a) deprotecting a compound of formula (II):



wherein n and R to R³ are as defined hereinabove, and X is a protecting group such as benzyl or trimethylsilyl or

(b) reacting a compound of formula (III):



wherein n and R to R³ are as defined hereinabove, and any hydroxy group is optionally protected, with hydroxylamine or a salt thereof, or

(c) converting a compound of formula (I) to a different compound of formula (I) as defined hereinabove.



5 Compounds of formulae (II) and (III) are novel and form a further aspect of the invention.

Compounds of formula (II) can be prepared from compounds of formula (III) by reaction with a protected hydroxylamine. Compounds of formula (III) having one or more protected hydroxy groups can be converted by hydrolysis to a corresponding unprotected compound of formula (III).


Suitable protecting groups for a hydroxamic acid are well known in the art and include benzyl, trimethylsilyl, t-butyl and t-butyldimethylsilyl.

Suitable protecting groups for a carboxylic acid are well known in the art and include t-butyl, benzyl and methyl.

15 Compounds of formula (III) can be prepared by reacting a compound of formula (IV) or (IVa):



wherein R and R¹ are as defined hereinabove and Y is a protecting group for carboxyl, with a compound of formula (V):




(V)

- wherein n , R^2 and R^3 are as defined hereinabove, or an activated derivative thereof. If (IVa) is used a subsequent alkylation or acylation of the hydroxyl group may then be required.

Compounds of formula (IV) can be prepared by protecting a corresponding compound in which Y is hydrogen, which in turn can be prepared by:

- (a) reacting a compound of formula (VI):




(VI)

- wherein R^1 is as defined hereinabove and Z is a protecting group for carboxyl, with an alkylating agent; and
- (b) removing the protecting groups.

- Compounds of formula (VI) wherein Z is hydrogen can be prepared by reacting a diester (such as the dimethyl or diethyl ester) of 2-hydroxy succinic acid with a compound of formula $\text{R}^1\text{X}'$ in the presence of a strong base such as lithium diisopropylamide, wherein X' is a leaving group such as bromine or iodine, and then hydrolysing the resulting compound to remove the ester groups.

- The isomers, including stereoisomers, of the compounds of the present invention may be prepared as mixtures of such isomers or as individual isomers. The individual isomers may be prepared by any appropriate method, for example individual stereoisomers may be prepared by stereospecific chemical synthesis starting from chiral substrates or by

separating mixtures of diastereoisomers using known methods. In a preferred aspect, the invention provides compounds of formula (IA):



(1A)

It is preferred that the compounds are isolated in substantially pure form.

As stated herein an inhibitor of the formation of soluble human CD23 has useful medical properties. Preferably the active compounds are administered as pharmaceutically acceptable compositions.

The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example in the form of a spray, aerosol or other conventional method for inhalation, for treating respiratory tract disorders; or parenteral administration for patients suffering from heart failure. Other alternative modes of administration include sublingual or transdermal administration.

The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.

Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.

The solid oral compositions may be prepared by conventional methods of blending, filling or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course
5 conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for
10 reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan
15 monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

20 For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
25 Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in
30 the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a

surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

Compositions of this invention may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for
5 a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns for example diameters in the range of 1-50 microns, 1-10 microns or 1-5 microns. Where appropriate, small
10 amounts of other anti-asthmatics and bronchodilators, for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.

15 The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration. A preferred range for inhaled administration is 10-99%, especially 60-99%, for example 90, 95 or 99%.

Microfine powder formulations may suitably be administered in an
20 aerosol as a metered dose or by means of a suitable breath-activated device.

Suitable metered dose aerosol formulations comprise conventional propellants, cosolvents, such as ethanol, surfactants such as oleyl alcohol, lubricants such as oleyl alcohol, desiccants such as calcium sulphate and density modifiers such as sodium chloride.

25 Suitable solutions for a nebulizer are isotonic sterilised solutions, optionally buffered, at for example between pH 4-7, containing up to 20mg/ml of compound but more generally 0.1 to 10mg/ml, for use with standard nebulisation equipment.

An effective amount will depend on the relative efficacy of the
30 compounds of the present invention, the severity of the disorder being treated and the weight of the sufferer. Suitably, a unit dose form of a composition of the invention may contain from 0.1 to 1000mg of a compound of the invention (0.001 to 10mg via inhalation) and more usually

from 1 to 500mg, for example 1 to 25 or 5 to 500mg. Such compositions may be administered from 1 to 6 times a day, more usually from 2 to 4 times a day, in a manner such that the daily dose is from 1mg to 1g for a 70 kg human adult and more particularly from 5 to 500mg. That is in the range
5 of about 1.4×10^{-2} mg/kg/day to 14 mg/kg/day and more particularly in the range of about 7×10^{-2} mg/kg/day to 7 mg/kg/day.

The following examples illustrate the invention but do not limit it in any way.

10

15

20

25

30

BIOLOGICAL TEST METHODS

Procedure 1: The ability of test compounds to inhibit the release of soluble CD23 was investigated by use of the following procedure.

5

RPMI 8866 Cell membrane CD23 cleavage activity assay:

Plasma membranes from RPMI 8866 cells, a human Epstein-Barr virus transformed B-cell line (Sarfati et al., Immunology 60 [1987] 539-547) expressing high levels of CD23 are purified using an aqueous extraction method. Cells resuspended in homogenization buffer (20mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl₂, 1 mM DTT) are broken by N₂ cavitation in a Parr bomb and the plasma membrane fraction mixed with other membranes is recovered by centrifugation at 10,000Xg. The light pellet is resuspended in 0.2 M potassium phosphate, pH 7.2 using 2 ml per 1-3 g wet cells and the nuclear pellet is discarded. The membranes are further fractionated by partitioning between Dextran 500 (6.4% w/w) and polyethylene glycol (PEG) 5000 (6.4% w/w) (ref), at 0.25 M sucrose in a total of 16 g per 10-15 mg membrane proteins [Morre and Morre, BioTechniques 7, 946-957 (1989)]. The phases are separated by brief centrifugation at 1000Xg and the PEG (upper) phase is collected, diluted 3-5 fold with 20 mM potassium phosphate buffer pH 7.4, and centrifuged at 100,000Xg to recover membranes in that phase. The pellet is resuspended in phosphate-buffered saline and consists of 3-4 fold enriched plasma membranes as well as some other cell membranes (e.g. lysosomes, Golgi). The membranes are aliquoted and stored at -80°C. Fractionation at 6.6 % Dextran/PEG yields plasma membranes enriched 10-fold.

The fractionated membranes are incubated at 37°C for times up to 4 hrs to produce fragments of CD23 which are separated from the membrane by filtration in 0.2 micron Durapore filter plates (Millipore) after quenching the assay with 5 uM Preparation 1 from P 30994. sCD23 released from the membrane is determined using the EIA kit from The Binding Site (Birmingham, UK) or a similar one utilizing MHM6 anti-CD23 mAb [Rowe et al., Int. J. Cancer, 29, 373-

382 (1982)] or another anti-CD23 mAb as the capture antibody in a sandwich EIA.. The amount of soluble CD23 made by 0.5 ug membrane protein in a total volume of 50 ul phosphate-buffered saline is measured by EIA and compared to the amount made in the presence of various concentrations of inhibitors.

- 5 Inhibitors are prepared in solutions of water or dimethylsulfoxide (DMSO) and the final DMSO concentration is not more than 2 %. IC₅₀'s are determined by curve fitting as the concentration where 50 % inhibition of production of sCD23 is observed relative to the difference in sCD23 between controls incubated without inhibitor.

10

Procedure 2: The ability of test compounds to inhibit collagenase was investigated using the following procedure.

Collagenase inhibition assay:

15

The potency of compounds to act as inhibitors of collagenase was determined by the method of Cawston and Barrett (Anal. Biochem. 99, 340-345, 1979), hereby incorporated by reference, whereby a 1 mM solution of the inhibitor being tested or dilutions thereof, was incubated at 37 °C for 18 h with collagen and human recombinant collagenase, from synovial fibroblasts cloned, expressed and purified from E. Coli, (buffered with 150 mM Tris, pH 7.6, containing 15 mM calcium chloride, 0.05% Brij 35, 200 mM sodium chloride and 0.02% sodium azide). The collagen was acetylated ³H type 1 bovine collagen prepared by the method of Cawston and Murphy (methods in Enzymology 80, 711,1981) The samples were

20 centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of 1mM inhibitor, or dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported as that concentration effecting 50% of the collagenase (IC₅₀).

25
30

Procedure 3: The ability of test compounds to inhibit TNF release was investigated using the following procedure.


Assay for inhibition of release of $\text{TNF}\alpha$ from human monocytes stimulated by lipopolysaccharide (LPS) endotoxin.

- 5 Human monocytes, cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum, are centrifuged at 1000Xg for 5 min and then resuspended in medium at 2×10^6 cells/ml. The cell suspension is aliquoted in 24 well plates, 1 ml per well. Compounds to be tested are dissolved in neat dimethyl sulfoxide (DMSO) and added to culture with the final DMSO concentration at 0.1 %.
- 10 Compounds are added to cells in triplicate wells. $\text{TNF}\alpha$ release is stimulated by addition of LPS to the cells at a final concentration of 200 ng/ml. Appropriate control cultures are set up in triplicates also. The plates are incubated for 18-20 hrs at 37° C, 5% CO_2 , then centrifuged at 1000 Xg for 5 min. A specific ELISA for human $\text{TNF}\alpha$ (SmithKline Beecham) is used to measure TNF levels in the
- 15 cell-free culture supernatants.

Preparation of N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide

20

a) 3S-t-Butoxycarbonyl-2R-(2-naphthylmethyl)propiolactone



- 25 (t-Butyl-(3R)-carboxy-4-(2-naphthyl)butyrate (10g, 31.9mmol) in THF (160ml) was stirred at -70°C under argon and lithium bis(trimethylsilyl)amide (63.7ml of 1M solution in THF, 63.7mmol) was added dropwise. The mixture was stirred at between -60°C and -70°C for 1hr and then cooled to -80°C and N-iodosuccinimide (7.17g, 31.9mmol) in THF (20ml) was added via cannula. The
- 30 mixture was allowed to warm to ~30°C over 1hr and was then quenched with saturated ammonium chloride solution. Ethyl acetate was added and the 2-phase mixture was stirred rapidly at room temperature for 1.5hrs. The layers were separated and the aqueous layer was extracted with ethyl acetate (2x) and the combined organic layers were washed with 5% sodium thiosulfate solution and
- 35 brine and then dried (Na_2SO_4) and evaporated. Chromatography on silica gel


(elution with 10% ethyl acetate in hexane) and trituration of the recovered product with hexane gave 5.70g of a white solid (63%).

MS (AP +ve) $M+Na = 335$

1H NMR ($CDCl_3$): 1.31 (9H, s), 3.29 (1H, dd, $J = 8.5, 14.6$ Hz), 3.38 (1H, dd, $J = 6.1, 14.6$ Hz), 4.06 (1H, m), 4.45 (1H, d, $J = 4.4$ Hz), 7.34 (1H, dd, $J = 1.7, 8.5$ Hz), 7.48 (2H, m), 7.68 (1H, s), 7.82 (3H, m).

b) N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide

10




To 3S-t-Butoxycarbonyl-2R-(2-naphthylmethyl)propiolactone (5.0g, 16.0mmol) and (S)-t-leucinamide (2.47g, 19.2mmol) were stirred together in THF (30ml) at room temperature for 48hrs. The THF was evaporated, ethyl acetate was added and the solution was washed with 2N HCl, water and brine and then dried ($MgSO_4$) and evaporated. The resulting solid was triturated with hexane and dried to give 6.373g of product (90%).

MS (ES +ve) $M+Na = 465$, $M+H = 443$
 1H NMR ($DMSO-d_6$): 0.91 (9H, s), 1.39 (9H, s), 2.85-3.20 (3H, m), 3.85 (1H, dd, $J = 5.0, 7.4$ Hz), 4.17 (1H, d, $J = 9.3$ Hz), 5.65 (1H, d, $J = 7.4$ Hz), 6.91 (1H, s), 7.29 (1H, s), 7.38-7.48 (3H, m), 7.69 (1H, s), 7.80-7.87 (4H, m).

Preparation of N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl-S-tert-leucine methylamide


25



Carried out via opening of 3S-t-Butoxycarbonyl-2R-(2-Naphthylmethyl)propiolactone with tert-leucine methylamide as in b) above to give product as a white solid.

MS (AP+ve) $M+H = 457$, $M+Na = 479$
 1H NMR ($DMSO-d_6$): 0.85 (9H, s), 1.41 (9H, s), 2.32 (3H, d, $J = 4.6$ Hz), 2.90 (1H, dd, $J = 6.5, 13.5$ Hz), 3.03 (1H, dd, $J = 8.6, 13.5$ Hz), 3.14 (1H, m), 3.88 (1H, dd, $J = 5.7, 7.3$ Hz), 4.12 (1H, d, $J = 9.3$ Hz), 5.62 (1H, d, $J = 7.5$ Hz), 7.36 (1H, m), 7.45 (2H, m), 7.60 (1H, m), 7.65 (1H, s), 7.77-7.90 (4H, m).

Preparation of N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide




- 5 Carried out via opening of 3S-t-Butoxycarbonyl-2R-(2-Naphthylmethyl)propiolactone with tert-leucine ethylamide as in b) to above give product as a white solid (86%).

MS (ES +ve) M+H = 471, M+Na = 493

- 10 ¹H NMR (DMSO-d₆): 0.84 (3H, t, J = 7.3Hz), 0.86 (9H, s), 1.41 (9H, s), 2.80-2.92 (3H, m), 3.03 (1H, dd, J = 8.5, 13.6Hz), 3.16 (1H, m), 3.88 (1H, dd, J = 5.8, 7.3Hz), 4.12 (1H, d, J = 9.4Hz), 5.63 (1H, d, J = 7.4Hz), 7.37 (1H, dd, J = 1.5, 8Hz), 7.44-7.47 (2H, m), 7.65 (1H, m), 7.70 (1H, m), 7.77-7.81 (4H, m).

- 15 **Preparation of 3S-Hydroxy-2R-(2-(7-fluoro)naphthylmethyl)succinic acid diethyl ester**

a) 2-Bromomethyl-6-fluoronaphthalene




20

6-Fluoro-2-methylnaphthalene (20.5 g, 128 mmol, prepared by adaptation of the method of Wolinska-Mocydlarz et al²) and NBS (22.8 g, 128 mmol) were heated at reflux for 16 hr in CCl₄ (210 mL) during which time, benzoyl peroxide (2.5 g)

- 25 was added portionwise. The cooled solution was filtered and evaporated and the residue was extracted thoroughly with hexane (4 x 250 mL). The extracts were decanted from tarry material, combined and evaporated to give the product as a yellow solid, 29.8 g (97 %).

- 30 ¹H NMR (CDCl₃): 4.65 (2H, s), 7.27 (1H, dt, J = 9, 3 Hz), 7.43 (1H, dd, J = 10, 2 Hz), 7.53 (1H, dd, J = 9, 1 Hz), 7.74-7.85 (3H, m).

b) 3S-Hydroxy-2R-(2-(7-fluoro)naphthylmethyl)succinic acid diethyl ester



- 5 A mixture of LHMDs soln (1.0M in THF, 262 mL) and THF (80 mL) was cooled to -72°C , and a solution of diethyl S-malate (23.7 g, 124.6 mmol) in THF (100 mL), was added dropwise keeping the reaction at $<-68^{\circ}\text{C}$. The mixture was allowed to warm to -40°C for 15 min and then re-cooled to -72°C . 2-Bromomethyl-6-fluoronaphthalene (29.8 g, 124.7 mmol) in THF 180 mL was added dropwise and the mixture was stirred overnight while slowly warming to room temp. The mixture was poured into 0.5 M HCl and extracted with Et_2O (2x), the combined extracts were washed with 0.5 M HCl, NaHCO_3 solution water and brine; dried (MgSO_4) and evaporated to an oil which was chromatographed on silica (hexane/ Et_2O , 0 to 35 %) giving the product as a gum which subsequently solidified, 17.3 g (40 %).
- 10 ^1H NMR (CDCl_3): 1.20 (3H, t, $J = 7$ Hz), 1.27 (3H, t, $J = 7$ Hz), 3.14 (1H, dd, $J = 12, 9$ Hz), 3.20-3.42 (3H, m), 4.09-4.29 (5H, m), 7.25 (1H, dt, $J = 9, 2.5$ Hz), 7.43 (2H, m), 7.73 (1H, s), 7.75-7.89 (2H, m).

20 References:

1. G M Carrera and D Garvey, J. Heterocyclic Chem, 1992, 29, 847.
2. J Wolinska-Mocydlarz, P Canonne and LC Leitch, Synthesis, 1974, 566.


25

Example 1

N'-[3S-(Allyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide

30


a) N-[4-t-Butoxy-3S-(allyloxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide



To a solution of N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide (221 mg, 0.5 mmol) in tBuOH (10 ml) was added allyl bromide (0.4 ml, 5 mmol) followed by NaH (60% dispersion in mineral oil, 22 mg). Stirred for 1h then poured into dil HCl and extracted with diethyl ether. The extracts were washed with water, dried (MgSO₄) and evaporated. The residue was chromatographed (50% ethyl acetate/hexane) to give the product as a white foam. MS (ES +ve) M+Na = 505, M+H = 483

¹H NMR (DMSO -d₆): 0.75 (9H, s), 1.30 (9H, s), 2.64 (1H, dd, J = 14,4.5 Hz), 2.90 (1H, dd, J = 14,10 Hz), 3.06-3.2 (1H, m), 3.69-3.75 (1H, obs), 3.74 (1H, d, J = 8 Hz), 3.89 (1H, d, J = 8 Hz), 4.03 (1H, d, J = 9 Hz), 5.02 (1H, dd, J = 10,2 Hz), 5.14 (1H, dd, J = 17,2 Hz), 5.64-5.75 (1H, m), 6.71 (1H, br), 7.03 (1H, br), 7.16 (1H, dd, J = 8.5,1.5 Hz), 7.28-7.33 (2H, m), 7.48 (1H, s), 7.62-7.71 (4H, m).


b) N-[3S-(Allyloxy)-4-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide



A solution of N-[4-t-Butoxy-3S-(allyloxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide (0.18g, 0.4 mmol) in dichloromethane/trifluoroacetic acid (5/2 ml) was stirred for 18h. Concentrated to yield product as a white solid. MS (ES +ve) M+Na = 449, M+H = 427

¹H NMR (DMSO-d₆): 0.9 (9H, s), 2.85 (1H, dd, J = 14,4.5 Hz), 3.05 (1H, dd, J = 14,10 Hz), 3.22-3.31 (1H, m), 3.85 (1H, dd, J = 12.5,5.5), 3.94 (1H, d, J = 8 Hz), 4.08 (1H, dd, J = 12.5,5 Hz), 4.17 (1H, d, J = 9 Hz), 5.15 (1H, d, J = 10Hz), 5.41 (1H, d, J = 17), 5.87-5.90 (1H, m), 6.87 (1H, br), 7.17 (1H, br), 7.33 (1H, d, J = 8.5 Hz), 7.43-7.47 (2H, m), 7.65 (1H, s), 7.62-7.71 (4H, m).

c) N'-[3S-(Allyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




A solution of N-[3S-(allyloxy)- 4-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide (0.96g, 2.25 mmol) in anhydrous DMF (10ml) was treated sequentially with HOAT (0.613g, 4.50 mmol) and EDC (0.846g, 4.50 mmol), and the reaction solution was stirred at room temperature for 0.25h. Hydroxylamine hydrochloride (0.47g, 6.75 mmol) and N-methylmorpholine (0.682g, 6.75 mmol) were then added and the reaction solution was stirred for 16h at room temperature. The reaction solution was evaporated to dryness and the residue was partitioned between ethyl acetate and 10% citric acid. The phases were separated and the organic phase was washed with further 10% citric acid (x2) and satd. sodium bicarbonate solution (x3). Precipitated product was filtered off, washed with water and ethyl acetate and then dried in vacuo to afford the title compound as a white solid (0.22g, 22%). The organic phase from the filtrate was washed with brine, dried (MgSO₄) and evaporated and the residue was recrystallised from methanol/diethyl ether to afford the title compound (0.26g, 26%).

MS (ES -ve) M-H = 440

¹H NMR (DMSO-d₆): 0.97 (9H, s), 2.64 (1H, m), 2.93 (1H, m), 3.23 (1H, m), 3.81 (2H, m), 3.95 (1H, m), 4.12 (1H, d, J = 9.4 Hz), 5.11 (1H, d, J = 10.6 Hz), 5.23 (1H, d, J = 17.3 Hz), 5.78 (1H, m), 6.75 (1H, s), 6.96 (1H, s), 7.25 (1H, d, J = 8.7 Hz), 7.43 (2H, m), 7.59 (1H, s), 7.65-7.83 (4H, m), 9.12 (1H, s), 10.95 (1H, s).

N-[3S-(Allyloxy)- 4-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide can also be prepared from (3R-Naphthylmethyl)-2S-hydroxy succinic acid diethyl ester as follows:-

d) 3S-Allyloxy-2R-naphthylmethylsuccinic acid diethyl ester



To a stirred solution of (3R-Naphthylmethyl)-2S-hydroxy succinic acid diethyl ester (4.0g, 12mmol) in benzene (80ml) was added thallium (I) ethoxide (2.99g, 12mmol) and the mixture was stirred at room temperature. A gelatinous precipitate was formed and after 1hr, the solvent was removed in vacuo. The precipitate was then suspended in DMF (120ml) and allyl bromide (1.45g, 1.04ml, 12mmol) was added and the mixture was stirred at room temperature overnight. The mixture was filtered to remove thallium salts, water and ethyl acetate were added and the product was extracted into ethyl acetate. The extracts were washed successively with water and brine and then dried (MgSO₄) and

concentrated. Purification by chromatography on silica gel (elution with 5% ethyl acetate in 40-60-petroleum ether) gave the product as an oil (1.40g, 32%).


MS (ES +ve) M+Na = 393

¹H NMR (CDCl₃): 1.10 (3H, t, J = 7.2 Hz), 1.29 (3H, t, J = 7.2 Hz), 3.03 (1H, dd, J = 6.9, 13.5 Hz), 3.16-3.33 (2H, m), 3.91 (1H, dd, J = 6.1, 12.6 Hz), 4.02-4.30 (6H, m), 5.20 (1H, dd, J = 1.3, 10.3 Hz), 5.28 (1H, dd, J = 1.6, 17.2 Hz), 5.91 (1H, m), 7.33 (1H, dd, J = 1.7, 8.4 Hz), 7.45 (2H, m), 7.64 (1H, s), 7.78 (3H, m).

e) Using known methodology e.g. WO9702239, 3S-Allyloxy-2R-naphthylmethylsuccinic acid diethyl ester can be hydrolysed, treated with trifluoroacetic anhydride then methanol, coupled to (S)-tert-leucinamide and hydrolysed to give N-[3S-(Allyloxy)-4-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide.
Spectral data as for example 1 b) above.

Example 2

N'-[3S-(Allyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




Prepared analogously to example 1 d) + e) from 3S-Allyloxy-2R-naphthylmethylsuccinic acid diethyl ester, but coupling with N-Methyl-(S)-tert-leucinamide instead of (S)-tert-leucinamide.

MS (ES +ve) M+H = 456, M+Na = 478

¹H NMR (DMSO-d₆): 0.81 (9H, s), 2.05 (3H, d, J = 4.4 Hz), 2.65 and 2.80 (2H, m), 3.25 (1H, m), 3.78 and 3.93 (2H, dd, J = 12.7, 5.4 Hz), 3.85 (1H, d, J = 9.7 Hz), 4.05 (1H, d, J = 9.5 Hz), 5.09 (1H, dd, J = 10.4, 1.6 Hz), 5.22 (1H, dd, J = 17.3, 1.6 Hz), 5.75 (1H, m), 7.12 (1H, d, J = 4.4 Hz), 7.24 (1H, m), 7.46 (2H, m), 7.57 (1H, s), 7.75 (4H, m), 9.14 (1H, s), 10.99 (1H, s).

Example 3

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(propyloxy)succinyl]-S-tert-leucine methylamide



5

Prepared analogously to example 2 from 3S-Allyloxy-2R-naphthylmethylsuccinic acid diethyl ester, but the compound was hydrogenated using Pd/BaSO₄ prior to hydroxamic acid formation.

MS (ES +ve) M+H = 458, M+Na = 480


10

¹H NMR (DMSO-d₆): 0.82 (12H, m), 1.43 (2H, m), 2.04 (3H, d, J = 4.4 Hz), 2.64 and 2.81 (2H, m), 3.25 (3H, m), 3.78 (1H, d, J = 9.6 Hz), 4.03 (1H, d, J = 9.4 Hz), 7.06 (1H, d, J = 4.4 Hz), 7.25 (1H, d, J = 8.5 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.62 (1H, d, J = 9.4 Hz), 7.80 (3H, m), 9.14 (1H, s), 10.95 (1H, s).

15

Example 4

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(propyloxy)succinyl]-S-tert-leucinamide



20

Prepared analogously to example 1 d) + e) from 3S-Allyloxy-2R-naphthylmethylsuccinic acid diethyl ester, but the compound was hydrogenated using Pd/BaSO₄ prior to hydroxamic acid formation.


MS (ES +ve) M+H = 444, M+Na = 466

25

¹H NMR (DMSO-d₆): 0.82 (3H, t, J = 7.5 Hz), 0.89 (9H, s), 1.45 (2H, m), 2.64 and 2.91 (2H, m), 3.12 - 3.40 (3H, m), 3.75 (1H, d, J = 9.5 Hz), 4.11 (1H, d, J = 9.5 Hz), 6.79 (1H, s), 6.97 (1H, s), 7.25 (1H, m), 7.44 (2H, m), 7.59 (1H, s), 7.73 (4H, m), 9.10 (1H, br s) and 10.95 (1H, s).

Example 5


N'-[3S-(Allyloxy)-4-(N-hydroxyamino)-2R-(2-(7-fluoro-naphthylmethyl)succinyl)]-S-tert-leucinamide



- 5 Prepared analogously to example 1 d) + e) from 3S-Hydroxy-2R-(2-(7-fluoro)naphthylmethyl)succinic acid diethyl ester.
 MS (ES -ve) M-H = 458
¹H NMR (DMSO-d₆): 0.89 (9H, s), 2.69 (1H, dd, J = 14,4 Hz), 2.95 (1H, dd, J = 14,10 Hz), 3.11-3.19 (1H, m), 3.74-3.81 (2H, m), 3.96 (1H, dd, J = 12.5,5 Hz),
 10 4.07 (1H, d, J = 9.5 Hz), 5.10 (1H, dd, J = 10,1 Hz), 5.22 (1H, dd, J = 16,1 Hz), 5.75-5.86 (1H, m), 6.69 (1H, s), 7.11 (1H, s), 7.24 (1H, d, J = 9.5 Hz), 7.33 (1H, dd, J = 9,2.5 Hz), 7.54 (1H, dd, J = 10.5,2.5 Hz), 7.59 (1H, s), 7.77 (1H, d, J = 8.5 Hz), 7.77-7.82 (1H, obs), 7.89 (1H, dd, J = 8.5,6 Hz), 9.12 (1H, s), 10.91 (1H, s).

Example 6


N'-[3S-(Ethoxy)-4-(N-hydroxyamino)-2R-(2-(7-fluoro-naphthylmethyl)succinyl)]-S-tert-leucinamide



- 20 Prepared analogously to example 1 d) + e) from 3S-Hydroxy-2R-(2-(7-fluoro)naphthylmethyl)succinic acid diethyl ester, alkylating with iodoethane instead of allyl bromide.
 MS (ES -ve) M-H = 446
¹H NMR (DMSO-d₆): 0.89 (9H, s), 1.05 (3H, t, J = 7 Hz), 2.63 (1H, dd, J = 14,3 Hz), 2.90 (1H, dd, J = 14,10.5 Hz), 3.17 (1H, dd, J = 9,3 Hz), 3.23-3.27 (1H m),
 25 3.31-3.47 (1H, m), 3.75 (1H, d, J = 9 Hz), 4.11 (1H, d, J = 9.5 Hz), 6.76 (1H, s), 6.93 (1H, s), 7.22 (1H, dd, J = 8.5,1 Hz), 7.32 (1H, dt, J = 8.5,2.5 Hz), 7.53-7.58 (1H, obs), 7.58 (1H, s), 7.65 (1H, d, J = 9 Hz), 7.78 (1H, d, J = 8.5 Hz), 7.90 (1H, dd, J = 9,6 Hz), 9.11 (1H, s), 10.94 (1H, s).

Example 7

N'-[4-(N-Hydroxyamino)-2R-(2-(7-fluoro)naphthylmethyl)-3S-(propyloxy)succinyl]-S-tert-leucinamide




- 5 Prepared analogously to example 5 from 3S-Hydroxy-2R-(2-(7-fluoro)naphthylmethyl)succinic acid diethyl ester, but hydrogenating using Pd/C prior to hydroxamic acid preparation.
- MS (ES -ve) M-H = 460
- ¹H NMR (DMSO-d₆): 0.82 (3H, t, J = 7.5 Hz), 0.89 (9H, s), 1.40-1.52 (2H, m),
- 10 2.63 (1H, dd, J = 14,3.5 Hz), 2.89 (1H, dd, J = 14,10 Hz), 3.15 - 3.37 (3H, m), 3.75 (1H, d, J = 9.5 Hz), 4.09 (1H, d, J = 9.5 Hz), 6.75 (1H, s), 6.91 (1H, s), 7.23 (1H, dd, J = 8,1 Hz), 7.32 (1H, dt, J = 8.5,2), 7.58 (1H, s), 7.49-7.60 (2H, m), 7.78 (1H, d, J = 8.5), 7.90 (1H, dd, J = 9,8 Hz), 9.10 (1H, br) and 10.91 (1H, br).

15

Example 8

N'-[3S-(Ethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




- 20 Prepared analogously to example 1 a) + b) + c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by alkylation with iodoethane instead of allyl bromide.
- MS (ES -ve) M-H = 460
- ¹H NMR (DMSO-d₆): 0.94 (9H, s), 1.06 (3H, t, J = 7 Hz), 2.68 (1H, dd, J =
- 25 14,4 Hz), 2.94 (1H, dd, J = 24,11 Hz), 3.05-3.19 (1H, m), 3.22-3.29 (1H, m), 3.36-3.47 (1H, m), 3.70 (1H, d, J = 8.5 Hz), 4.09 (1H, d, J = 9.5 Hz), 6.78 (1H, s), 7.22 (1H, s), 7.28 (1H, d, J = 8.5 Hz), 7.42-7.48 (2H, m), 7.61 (1H, s), 7.76 (1H, d, J = 8.5 Hz), 7.80-7.87 (3H, m), 8.97 (1H, s), 10.92 (1H, s).

30

Example 9


N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(propyloxy)succinyl]-S-(β,β-dimethyl-Nε-methyllysineamide).TFA salt



- 5 Prepared analogously to example 1 d) + e) from 3S-Allyloxy-2R-naphthylmethylsuccinic acid diethyl ester, but the compound was coupled with β,β-dimethyl-Nε-methyl-lysineamide (instead of (S)-tert-leucineamide) and was hydrogenated using Pd/BaSO₄ prior to hydroxamic acid formation.
- 10 MS (ES -ve) M-H = 499, MS (ES +ve) M+H = 501
¹H NMR (DMSO-d₆): 0.84 (3H, t, J = 7.4 Hz), 0.86 (6H, s), 1.22 (2H, m), 1.48 (2H, m), 1.55 (2H, m), 2.55 (3H, s), 2.70 (3H, m), 2.93 (1H, m), 3.21 (2H, m), 3.35 (1H, m, partially obscured by water), 3.76 (1H, d, J = 8.9 Hz), 4.17 (1H, d, J = 9.5 Hz), 6.82 (1H, s), 6.95 (1H, s), 7.27 (1H, m), 7.43 (2H, m), 7.59 (1H, s),
 15 7.76 (4H, m), 8.25 (2H, br s), 9.12 (1H, s), 10.91 (1H, s).

Example 10

- 20 **N'-[4-(N-Hydroxyamino)-2R-(2-(6-fluoro)naphthylmethyl)-3S-(propyloxy)succinyl]-S-tert-leucineamide**




- Prepared analogously to example 1 d) + e) from 2R-(2-(6-Fluoro)naphthylmethyl)-3S-hydroxy succinic acid diethyl ester, the compound
 25 being hydrogenated using Pd/C prior to hydroxamic acid formation.
 MS (ES -ve) M-H = 460, MS (ES +ve) M+H = 462
¹H NMR (DMSO-d₆): 0.82 (3H, t, J = 7 Hz), 0.88 (9H, s), 1.45 (2H, m), 2.63 (1H, br d, J ≈ 12Hz), 2.89 (1H, br t), 3.20 (2H, m), ca 3.3 (1H, m, *partially obscured by water signal*), 3.76 (1H, d, J = 9 Hz), 4.08 (1H, d, J = 9Hz), 6.71 (1H, br s), 6.89 (1H, br s), 7.28-7.36 (2H, m), 7.58-7.63 (3H, m), 7.74 (1H, d, J = 8 Hz), 7.86-7.89 (1H, m), 9.09 (1H, br s), 10.90 (1H, br s).
 30

Example 11

N'-[3S-(Allyloxy)-4-(N-Hydroxyamino)-2R-(2-(6-Fluoro-naphthylmethyl)succinyl]-S-tert-leucinamide

5




Prepared analogously to example 1 d) + e) from 2R-(2-(6-Fluoro)naphthylmethyl)-3S-hydroxy succinic acid diethyl ester.

- 10 MS (ES -ve) M-H = 458, MS (ES +ve) M+H = 460
¹H NMR (DMSO-d₆): 0.87 (9H, s), 2.64 (1H, dd, J = 14, 3 Hz), 2.90 (1H, dd, J ≈ 14, 14 Hz), 3.22 (1H, m), 3.78 (1H, dd, J = 13, 6 Hz), 3.82 (1H, d, J = 10 Hz), 3.95 (1H, dd, J = 13, 5 Hz), 4.10 (1H, d, J = 9Hz), 5.10 (1H, d, J = 10 Hz), 5.22 (1H, dd, J = 17, 1 Hz), 5.73-5.83 (1H, m), 6.71 (1H, br s), 6.92 (1H, br s), 7.29 (1H, d, J = 8 Hz), 7.34 (1H, m), 7.58-7.67 (3H, m), 7.74 (1H, d, J = 8 Hz), 7.88 (1H, m), 9.10 (1H, br s), 10.95 (1H, br s).
- 15

Example 12

N'-[3S-(Hexyloxy)-4-(N-Hydroxyamino)-2R-(2-(6-Fluoro-naphthylmethyl)succinyl]-S-tert-leucinamide

20




Prepared analogously to example 1 d) + e) from 2R-(2-(6-

- 25 Fluoro)naphthylmethyl)-3S-hydroxy succinic acid diethyl ester, alkylating using hexyl iodide instead of allyl bromide.
 MS (ES -ve) M-H = 502, MS (ES +ve) M+H = 504, M + Na = 526
¹H NMR (DMSO-d₆): 0.85 (3H, t, J = 7 Hz), 0.88 (9H, s), 1.22 (6H, br m), 1.43 (2H, m), 2.64 (1H, m), 2.90 (1H, m), 3.20 (2H, m), 3.35 (1H, m), 3.75 (1H, d, J = 9 Hz), 4.08 (1H, d, J = 9 Hz), 6.72 (1H, b. s), 6.90 (1H, br s), 7.27-7.39 (2H, m), 7.57-7.65 (3H, m), 7.74 (1H, d, J = 9 Hz), 7.87 (1H, m), 9.10 (1H, br s), 10.90 (1H, br s).
- 30

Example 13

N'-[3S-((4-Fluoro)benzyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




Prepared analogously to example 1a) + b) + c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by alkylation with 4-Fluorobenzylbromide instead of allyl bromide.

MS (ES -ve) M-H = 508, MS (ES +ve) M+H = 510, M + Na = 532

¹H NMR (DMSO-d₆): 0.76 (9H, s), 2.69 (1H, m), 2.95 (1H, m), 3.25 (1H, m), 3.94 (1H, d, J = 9 Hz), 4.09 (1H, d, J = 9 Hz), 4.30 (1H, A of Abq, J = 11 Hz), 4.46 (1H, B of Abq, J = 11 Hz), 6.75 (1H, br s), 6.98 (1H, br s), 7.13 (2H, m), 7.24-7.35 (3H, m), 7.42-7.46 (2H, m), 7.60 (1H, br s), 7.66 (1H, d, J ≈ 10 Hz), 7.74 (1H, d, J = 8 Hz), 7.81 (2H, m), 9.17 (1H, br s), 11.00 (1H br s).

Example 14

N'-[3S-((4-Fluoro)benzyloxy)-4-(N-hydroxyamino)-2R-(2-(6-fluoro)naphthylmethyl)succinyl]-S-tert-leucinamide




Prepared analogously to example 1 d) + e) from 2R-(2-(6-Fluoro)naphthylmethyl)-3S-hydroxy succinic acid diethyl ester, alkylating using 4-Fluorobenzylbromide instead of allyl bromide.

MS (ES -ve) M-H = 526, MS (ES +ve) M+H = 528

¹H NMR (DMSO-d₆): 0.76 (9H, s), 2.68 (1H, m), 2.93 (1H, m), 3.27 (1H, m), 3.95 (1H, d, J = 10 Hz), 4.08 (1H, d, J = 8 Hz), 4.28 (1H, A of Abq, J = 11 Hz), 4.46 (1H, B of Abq, J = 11 Hz), 6.73 (1H, br s), 6.93 (1H, br s), 7.12 (2H, m), 7.29-7.39 (4H, m), 7.57-7.68 (3H, m), 7.74 (1H, d, J = 9 Hz), 7.89 (1H, m), 9.17 (1H, br s), 11.00 (1H, br s).

Example 15

N'-[3S-Benzoyloxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




Prepared as for example 1a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by acylation with benzoyl chloride instead of alkylation with allyl bromide.

MS (ES -ve) M-H = 504, MS (ES +ve) M+H = 506, M+Na = 528

¹H NMR (DMSO-d₆): 0.73 (9H, s), 2.73-2.89 (1H, m), 3.00-3.10 (1H, m), 3.58-3.67 (1H, m), 4.10 (1H, d, J = 9 Hz), 5.21 (1H, d, J = 10 Hz), 6.73 (1H, br s), 7.10 (1H, br s), 7.31 (1H, d, J = 9 Hz), 7.43-7.52 (4H, m), 7.65 (2H, m), 7.74-7.85 (3H, m), 8.04 (3H, m), 9.15 (1H, s), 11.22 (1H, s).

Example 16

N'-[3S-(2-(N,N-Dimethylacetamidoxy))-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




Prepared analogously to example 1 a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by alkylation with 2-Bromo-N,N-dimethylacetamide instead of allyl bromide.

MS (ES -ve) M-H = 485, MS (ES +ve) M+H = 487, M+Na = 509

¹H NMR (DMSO-d₆): 0.85 (9H, s), ca 2.75-2.83 (1H, m), 2.79 (3H, s), 2.91 (3H, s), 3.01 (1H, dd, J = 14, 10 Hz), ca 3.3 (1H, m), 3.94 (1H, d, J = 8 Hz), 4.06-4.15 (3H, m), 6.78 (1H, s), 7.03 (1H, s), 7.29 (1H, d, J = 8 Hz), 7.39-7.46 (2H, m), 7.63 (1H, s), ca 7.64 (1H, d, J = 8 Hz), 7.75 (1H, d, J = 8 Hz), 7.79-7.83 (2H, m), 9.09 (1H, s), 11.18 (1H, br m).

Example 17

N'-[3S-(2-(N-t-Butylacetamidoxo))-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide



5

Prepared analogously to example 1 a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by alkylation with bromoacetonitrile instead of allyl bromide and subsequent treatment with TFA prior to hydroxamic acid preparation.

10


MS (ES -ve) M-H = 508, MS (ES +ve) M+H = 510, M+Na = 532

¹H NMR (DMSO-d₆): 0.89 (9H, s), 1.29 (9H, s), 2.67-2.75 (1H, m), 2.90-2.96 (1H, m), *ca* 3.33 (1H, m), 3.62 & 3.78 (2x1H, Abq, J ≈ 15 Hz), 3.93 (1H, d, J = 9Hz), 4.22 (1H, d, J = 10Hz), 6.82 (1H, s), 7.04 (1H, s), 7.11 (1H, s), 7.27 (1H, d, J = 8 Hz), 7.41-7.47 (2H, m), 7.60 (1H, s), 7.75 (1H, d, J = 9 Hz), 7.81-7.84 (2H, m), 7.90 (1H, d, J = 8 Hz), 9.19 (1H, s), 11.13 (1H, br s).

15

Example 18

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(N-phenylcarbamoyloxy)-succinyl]-S-tert-leucinamide



20

Prepared analogously to example 1 a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by acylation with phenylisocyanate/DMAP instead of alkylation with allyl bromide.

MS (ES -ve) M-H = 519, MS (ES +ve) M+H = 521


25

¹H NMR (DMSO-d₆): 0.83 (9H, s), 2.76 (1H, dd, J = 12,4 Hz), 2.95-3.08 (1H, m), 3.36-3.41 (1H, m), 4.17 (1H, d, J = 9.5 Hz), 5.17 (1H, d, J = 9.5 Hz), 6.78 (1H, br), 6.91-7.00 (1H, m), 7.19 (1H, br), 7.22-7.32 (3H, m), 7.41-7.45 (4H, m), 7.6-7.7 (1H, obs), 7.61 (1H, s), 7.75 (1H, d, J = 9.5 Hz), 7.76-7.82 (2H, m), 9.08 (1H, s), 9.62 (1H, br), 11.09 (1H, br).

30

Example 19

N'-[4-(N-Hydroxyamino)-3S-(N-methyl-N-phenylcarbamoyloxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




- 5 Prepared analogously to example 1 a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by acylation with N-methyl-N-Phenylcarbamoyl chloride/NaH instead of alkylation with allyl bromide (see example 27).
 MS (ES -ve) M-H = 533, MS (ES +ve) M+H = 535
 10 ¹H NMR (DMSO-d₆): 0.78 (9H, s), 2.76 (1H, dd, J = 14,4 Hz), 2.98 (1H, dd, J = 14,10.5 Hz), 3.26 (3H,s), 3.35-3.41 (1H, m), 4.10 (1H, d, J = 9 Hz), 5.03 (1H, d, J = 9 Hz), 6.72 (1H, s), 7.06 (1H, s), 7.18 (1H, t, J = 6 Hz), 7.25-7.38 (5H, m), 7.38-7.46 (3H, m), 7.60 (1H, s), 7.74 (1H, d, J = 9 Hz), 7.79-7.90 (2H, m), 9.08 (1H, s), 11.02 (1H, br.).


15

Example 20

N'-[3S-(Cyclohexyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide



- 20 a) N-[4-t-Butoxy-3S-(cyclohexyloxy)-2R-(2-Naphthylmethyl)succinyl]-S-tert-leucinamide



- A solution of N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide (1.0g, 2.26mmol) and 3-bromocyclohexene (2.60ml, 22.6mmol) in N-methylpyrrolidinone (18ml) was stirred at 0°C under argon and lithium bis(trimethylsilyl)amide (2.50ml of 1M solution in THF, 2.50mmol) was added dropwise. The mixture was stirred at 0°C for 10 minutes and then at room temperature for 2.5hrs. The mixture was diluted with ethyl acetate/1N HCl and


the product was extracted into ethyl acetate. The organic extracts were washed with saturated NaHCO_3 solution, water (3x) and brine and then dried (Na_2SO_4) and concentrated. Trituration with hexane to remove excess alkylating agent, followed by chromatography on silica gel (elution with 1:1 ethyl acetate/hexane) gave the product as a foam (378mg) MS (ES +ve) $\text{M}+\text{H} = 523$.

This product (340mg), cyclohexene (1.5ml) and 10% Pd-C (30mg) in methanol (15ml) were refluxed together under argon overnight. After cooling, the mixture was filtered through Celite and concentrated to give a white solid (310mg).

MS (ES +ve) $\text{M}+\text{H} = 525$.

^1H NMR (CDCl_3): 1.09 (9H, s), 1.15-2.0 (10H, m), 1.42 (9H, s), 3.0-3.10 (2H, m), 3.20-3.30 (2H, m), 3.86 (1H, d, $J = 3.0$ Hz), 4.10 (1H, d, $J = 8.5$ Hz), 5.06 (1H, s), 6.55 (1H, s), 7.36-7.50 (4H, m), 7.67 (1H, s), 7.70-7.85 (3H, m).

b) N'-[3S-(Cyclohexyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide



A solution of N-[4-t-Butoxy-3S-(cyclohexyloxy)-2R-(2-Naphthylmethyl)succinyl]-S-tert-leucinamide (310mg) in dichloromethane (5ml)/trifluoroacetic acid (2ml) was stirred at room temperature for 4 hours. The solvents were evaporated and the product was re-evaporated from toluene (3x) to give the carboxylic acid as a colourless glassy solid.

This product in DMF (10ml) was treated with EDC (0.23g, 1.18mmol) and HOAT (0.16g, 1.18mmol) followed by a solution of hydroxylamine hydrochloride (0.12g, 1.77mmol) and N-methylmorpholine (0.20ml, 1.77mmol) in DMF (5ml).


The mixture was stirred at room temperature overnight and then concentrated on the rotary evaporator. The residue was partitioned between ethyl acetate/1N HCl and the product was extracted into ethyl acetate. The extracts were washed with 1N HCl, water and brine and then dried (MgSO_4) and evaporated. Trituration with ether gave a white solid (94mg).

MS (ES -ve) $\text{M}-\text{H} = 482$

^1H NMR ($\text{DMSO}-d_6$): 0.90 (9H, s), 1.0-1.95 (10H, m), 2.68 (1H, dd, $J = 3.9, 13.8$ Hz), 2.92 (1H, dd, $J = 10.6, 13.8$ Hz), 3.10-3.20 (2H, m), 3.95 (1H, d, $J = 9.0$ Hz), 4.04 (1H, d, $J = 9.3$ Hz), 6.72 (1H, s), 6.88 (1H, s), 7.27 (1H, d, $J = 9$ Hz), 7.43 (2H, m), 7.60 (2H, m), 7.74 (1H, d, $J = 8.5$ Hz), 7.81 (2H, m), 9.04 (1H, s), 10.86 (1H, s).

Example 21

N'-[3S-(Cyclohexyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide




5

Prepared from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide by alkylation, hydrogenation, t-butyl ester cleavage and hydroxamic acid formation analogously to Example 20 to give N'-[3S-

10 (Cyclohexyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide.
MS (ES -ve) M-H = 510
¹H NMR (DMSO-d₆): 0.65 (3H, t, J = 7.2Hz), 0.85 (9H, s), 1.0-1.25 (5H, m),
15 1.47 (1H, m), 1.65 (2H, m), 1.75 (1H, m), 1.85 (1H, m), 2.45-2.69 (3H, m), 2.83 (1H, m), 3.20 (2H, m), 3.96 (1H, d, J = 9.2Hz), 3.98 (1H, d, J = 9.1Hz), 7.12 (1H, m), 7.26 (1H, dd, J = 1.1, 8.3Hz), 7.43 (2H, m), 7.53 (1H, d, J = 10Hz), 7.58 (1H, s), 7.72-7.85 (3H, m), 9.07 (1H, s), 10.85 (1H, s).

Example 22

N'-[3S-(Ethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




Prepared analogously to Example 1) a) + b) + c) from N-4-t-Butoxy-3S-

25 (hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with iodoethane instead of allyl bromide.
MS (ES -ve) M-H = 442
¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.04 (3H, t, J = 7.0Hz), 2.07 (3H, d, J =
4.5Hz), 2.64 (1H, dd, J = 3.8, 13.6Hz), 2.83 (1H, m), 3.20-3.27 (2H, m), 3.44 (1H,
30 m), 3.77 (1H, d, J = 9.6Hz), 4.05 (1H, d, J = 9.8Hz), 7.06 (1H, m), 7.24 (1H, dd, J = 1.5, 8.4Hz), 7.44 (2H, m), 7.56 (1H, s), 7.59 (1H, d, J = 10Hz), 7.72-7.85 (3H, m), 9.08 (1H, s), 10.92 (1H, s).

Example 23


N'-[4-(N-Hydroxyamino)-2R-(2-Naphthylmethyl)-3S-((3-phenyl)propyloxy)-succinyl]-S-tert-leucinamide



- 5 Prepared analogously to Example 1 a) + b) + c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by alkylation with cinnamyl bromide, followed by reduction, deprotection and hydroxamic acid formation.
MS (ES +ve) M+H = 520, MS (ES -ve) M-H = 518
¹H NMR (DMSO-d₆): 0.9 (9H, s), 1.70-1.80 (2H, m), 2.50-2.70 (3H, m), 2.85-2.95 (1H, m), 3.18-3.3 (2H, m), 3.35-3.45 (1H, m), 3.75 (1H, d, J = 9.4 Hz), 4.10 (1H, d, J = 9.5 Hz), 6.75 (1H, s), 6.95 (1H, s), 7.10-7.20 (3H, m), 7.25-7.30 (3H, m), 7.35-7.45 (2H, m), 7.60 (1H, s), 7.68-7.85 (4H, m), 9.10 (1H, s), 10.9 (1H, s).
- 10

Example 24


N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(thiazol-2-ylmethoxy)succinyl]-S-tert-leucinamide



- 15 Prepared analogously to Example 1 a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by alkylation with 2-bromomethylthiazole instead of allyl bromide.
MS (ES +ve) M+H = 499, MS (ES -ve) M-H = 497
¹H NMR (DMSO-d₆): 0.80 (9H, s), 2.65-2.70 (1H, m), 2.88-2.97 (1H, m), 3.30-3.50 (1H, m), 4.05 (1H, d, J = 9.6 Hz), 4.10 (1H, d, J = 9.3 Hz), 4.65 (1H, d, J = 12.9 Hz), 4.75 (1H, d, J = 12.94 Hz), 6.70 (1H, s), 6.95 (1H, s), 7.25 (1H, d, J = 8.6 Hz), 7.40-7.50 (2H, m), 7.60 (1H, s), 7.70-7.80 (4H, m), 7.80-7.88 (2H, m), 9.20 (1H, s), 11.05 (1H, s).
- 20
- 25

Example 25

N'-[3S-(Cyclohexylcarbonyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide



5

Prepared analogously to Example 1a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by acylation with cyclohexoyl chloride instead of alkylation with allyl bromide (see example 27).

10 MS (ES +ve) M+H = 512


¹H NMR (DMSO-d₆): 0.88 (9H, s), 1.10-1.38 (5H, m), 1.50-1.88 (5H, m), 2.22 (1H, m), 2.80 (1H, dd, J = 4,14 Hz), 2.97 (1H, dd, J = 10,14 Hz), 3.41 (1H, m), 4.09 (1H, d, J = 9 Hz), 4.90 (1H, d, J = 10 Hz), 6.76 (1H, s), 7.01 (1H, s), 7.28 (1H, d), 7.47 (2H, m), 7.61 (1H, s), 7.74 (1H, d, J = 9 Hz), 7.82 (3H, m), 9.07 (1H, s), 11.01 (1H, s).

15

Example 26

N'-[3S-(t-Butylcarbonyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide

20



Prepared analogously to Example 1a) + b) + c) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide by acylation with pivaloyl chloride instead of alkylation with allyl bromide (see example 27).

25


MS (ES +ve) M+H = 486

¹H NMR (DMSO-d₆): 0.87 (9H, s), 1.11 (9H, s), 2.84 (1H, dd, J = 5,14 Hz), 2.93 (1H, dd, J = 9,14 Hz), 4.03 (1H, d, J = 9 Hz), 4.95 (1H, d, 9 Hz), 6.73 (1H, s), 6.99 (1H, s), 7.31 (1H, d, J = 8 Hz), 7.44 (2H, m), 7.64 (1H, s), 7.75 (1H, d, J = 9 Hz), 7.81 (3H, m), 9.05 (1H, s), 11.00 (1H, s).

30

Example 27**N'-[3S-benzoyloxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide**

- 5 a) N-[3S-benzoyloxy-4-t-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




- 10 To a solution of N-[4-t-Butoxy-3S-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide (0.3 g, 0.678 mmol) in DME (5 mL) was added NaH (60% suspension in mineral oil, 0.03 g, 0.75 mmol) followed after 30 sec. by benzoyl chloride (0.087 mL, 0.075 mmol). The mixture was stirred for 1 hr at room temp and then poured into 0.5 M HCl and extracted (2x) with EtOAc. The extracts were
- 15 washed with Na HCO₃ soln, water and brine; dried (MgSO₄) and evaporated to a foam which crystallised on addition of ether. The product was obtained as a white crystalline solid, 0.33 g (89%).

MS (ES +ve) M+H = 547, (M+Na) = 569

¹H NMR (DMSO-d₆): 0.85 (9H, s), 1.40 (9H, s), 3.00 (1H, m), 3.18 (1H, m),

- 20 3.65 (1H, m), 4.20 (1H, d, J = 8Hz), 5.04 (1H, d, J = 7Hz), 6.89 (1H, br. s), 7.34 (1H, br. s), 7.38-7.53 (5H, m), 7.67-7.72 (2H, m), 7.78-7.88 (3H, m), 7.98 (2H, d, J = 8 Hz), 8.06 (1H, d, J = 8 Hz).

- b) N'-[3S-Benzoyloxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide
- 25



- 30 Prepared from N-[3S-Benzoyloxy-4-t-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide analogously to example 1 b) + c).


MS (ES -ve) M-H = 504, MS (ES +ve) M+H = 506, M + Na = 528

¹H NMR (DMSO-d₆): 0.73 (9H, s), 2.73-2.89 (1H, m), 3.00-3.10 (1H, m), 3.58-3.67 (1H, m), 4.10 (1H, d, J = 9 Hz), 5.21 (1H, d, J = 10 Hz), 6.73 (1H, br s), 7.10

(1H, br s), 7.31 (1H, d, J = 9 Hz), 7.43-7.52 (4H, m), 7.65 (2H, m), 7.74-7.85 (3H, m), 8.04 (3H, m), 9.15 (1H, s), 11.22 (1H, s).

5 Example 28

N'-[3S-(Ethoxy)-4-(N-hydroxyamino)-2R-(2-quinolinylmethyl)succinyl]-S-tert-leucine methylamide



10

A solution of N'-[3S-(Ethoxy)-4-(N-hydroxy)-2R-(2-quinolinylmethyl)succinyl]-S-tert-leucine methylamide hydrochloride (prepared analogously to example 1 b from 3-(3-quinoline)propionic acid, 0.19g, 0.42 mmol) in anhydrous DMF (5ml) was treated sequentially with HOAT (0.11g, 0.84 mmol) and EDC (0.16g, 0.84 mmol), and the solution was stirred at room temperature for 0.25h.

15

Hydroxylamine hydrochloride (0.09g, 1.26 mmol) and N-methylmorpholine (0.18 ml, 1.35 mmol) were then added and the solution was stirred for 3h at room temperature. The solution was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The phases were separated and the organic phase was washed with further water and sat^d. sodium bicarbonate solution and dried with brine and over magnesium sulfate. The organic phase was then evaporated and dried in the drying pistol at 50°C for 3 hours to afford the title compound as a white solid (0.01g, 5%).

20

MS (ES +ve) M+H = 445

25


¹H NMR (DMSO-d₆): 0.82 (9H, s), 1.04 (3H, t, J = 6.9Hz), 2.06 (3H, d, J = 4.5), 2.72 (1H, m), 2.75 (1H, m), 3.26 (1H, m), 3.31 (1H, m), 3.44 (1H, m), 3.80 (1H, d, J = 9.7 Hz), 4.05 (1H, d, J = 9.6 Hz), 7.22 (1H, q, J = 5.6 Hz), 7.53 (1H, t, J = 6.0 Hz), 7.66 (1H, d, J = 6.6 Hz), 7.70 (1H, t, J = 7.3 Hz), 7.84 (1H, d, J = 6.7 Hz), 7.94 (1H, d, 7.9 Hz), 7.97 (1H, s), 8.60 (1H, d, H = 2 Hz), 9.11 (1H, s), 10.96

30

(1H, s).

Example 29

N'-[4-(N-Hydroxyamino)-3S-methoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



5

Prepared analogously to example 1) a) + b) + c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with iodomethane instead of allyl bromide.

10 MS (ES +ve) M+H = 430


¹H NMR (DMSO-d₆): 0.83 (9H, s), 2.10 (3H, d, J = 4.5 Hz), 2.63 (1H, dd, J = 4, 14 Hz), 2.84 (1H, dd, J = 11, 14 Hz), 3.17 (3H, s), 3.20 (1H, m), 3.67 (1H, d, J = 10 Hz), 4.08 (1H, d, J = 10 Hz), 7.14 (1H, q, J = 4.5 Hz), 7.25 (1H, m), 7.43 (2H, m), 7.56 (1H, s), 7.61 (1H, d, J = 10 Hz), 7.80 (3H, m), 9.09 (1H, s), 10.94 (1H, s).

15

Example 30

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)succinyl-3S-propanoyloxy] - S-tert-leucine methylamide

20



Prepared analogously to example 27 from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by acylation with propanoyl chloride instead of benzoyl chloride.


25 MS (APCI+ve) M+Na = 494

¹H NMR (DMSO-d₆): 0.82 (9H, s), 0.99 (3H, t, J = 7.5 Hz), 2.07 (3H, d, J = 4.5 Hz), 2.22 (2H, m), 2.78 (1H, dd, J = 4, 13.5 Hz), 2.88 (1H, dd, J = 11, 14 Hz), 3.42 (1H, m), 4.03 (1H, d, J = 9 Hz), 4.96 (1H, d, J = 10 Hz), 7.16 (1H, q, J = 4.5 Hz), 7.25 (1H, m), 7.44 (2H, m), 7.57 (1H, s), 7.80 (4H, m), 9.09 (1H, s), 11.07 (1H, s).

30

Example 31

N'-[3S-(Ethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide



5

Prepared analogously to example 1) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide by alkylation with iodoethane instead of allyl bromide, then cleavage of the tert-butyl ester and hydroxamic acid formation.

10


MS (ES -ve) M-H = 456

¹H NMR (DMSO-d₆): 0.67 (3H, t, J = 7.0 Hz), 0.84 (9H, s), 1.05 (3H, t, J = 7.0 Hz), 2.55 (1H, m), 2.65 (2H, m), 2.82 (1H, t, J = 11.0 Hz), 3.17-3.30 (2H, m, partially obscured), 3.44 (1H, m), 3.77 (1H, d, J = 9.5 Hz), 4.05 (1H, d, J = 9.5 Hz), 7.23-7.25 (2H, m), 7.38-7.48 (2H, m), 7.56-7.59 (2H, m), 7.72 (1H, d, J = 8.5 Hz), 7.76-7.83 (2H, m), 9.08 (1H, s), 10.93 (1H, s).

15

Example 32

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(2-methylpropoxy)succinyl]-S-tert-leucine methylamide



25

Prepared analogously to example 1) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with methylallyl bromide, hydrogenation, tert butyl ester cleavage and hydroxamic acid formation.


30

MS (ES -ve) M-H = 470

¹H NMR (DMSO-d₆): 0.79-0.83 (6H, m), 0.83 (9H, s), 1.72 (1H, m), 2.04 (3H, d, J = 4.5 Hz), 2.65 (1H, dd, J = 4.0, 13.5 Hz), 2.82 (1H, dd, J = 11.0, 13.5 Hz), 3.04 (1H, dd, 6.5, 9.0 Hz), 3.12 (1H, dd, J = 7.5, 9.0 Hz), 3.26 (1H, m), 3.78 (1H, d, J = 9.5 Hz), 4.00 (1H, d, J = 9.3 Hz), 6.99 (1H, m), 7.27 (1H, dd, J = 1.5, 8.5 Hz), 7.44 (2H, m), 7.55 (1H, d, J = 10.5 Hz), 7.57 (1H, s), 7.74 (1H, d, J = 8.5 Hz), 7.77-7.85 (2H, m), 9.09 (1H, s), 10.88 (1H, s).

Example 33

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-propoxysuccinyl]-S-tert-leucine ethylamide



N'-[4-Hydroxy-2R-(2-naphthylmethyl)-3S-propoxysuccinyl]-S-tert-leucine ethylamide (0.17 g, 0.372 mmol) (prepared analogously to example 1) from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide by alkylation with allyl bromide, hydrogenation, then cleavage of the tert-butyl ester) was treated with HOAT (0.1 g 0.735 mmol), DEC (0.142 g, 0.74 mmol), hydroxylamine hydrochloride (0.078 g, 1.12 mmol) and N-methylmorpholine (0.123 mL, 1.12 mmol), in DMF (4.3 mL), in the standard manner. Normal work-up procedure gave the product as a white solid, 0.1 g, (57%).


MS (ES +ve) M+H = 472, M+Na = 494.

¹H NMR (DMSO-d₆): 0.66 (3H, t, J = 7 Hz), 0.82 (3H, t, J = 7.5 Hz), 0.84 (9H, s), 1.45 (2H, sextet, J = 7 Hz), 2.53 (1H, m), 2.65 (2H, m), 2.84 (1H, m), 3.20 (2H, m) ca. 3.30 (1H, m, partially obs.), 3.77 (1H, d, J = 9.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 7.21 (1H, br. t, J ≈ 4 Hz), 7.25 (1H, dd, J = 8.5, 1.5 Hz), 7.43 (2H, m), 7.56 (1H, d, J = 8.5 Hz), 7.57 (1H, s), 7.72 (1H, d, J = 8.5 Hz), 7.75-7.83 (2H, m), 9.10 (1H, s), 10.89 (1H, br. s).

Example 34

N'-[3S-tert-Butoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide

a) **N'-[4-(N-Benzoyloxyamino)-3S-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide**




- 5 N'-[3S,4-Dihydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (1.5 g, 3.75 mmol) in DMF (25 mL), was treated with HOBT (1.15 g, 7.51 mmol), and DEC (1.44 g, 7.51 mmol). After stirring the mixture for 20 min., O-benzylhydroxylamine (0.92 mL), was added. The reaction was stirred at room temp. for 6 hr., and the DMF was then removed in vacuo. To the residue was added NaHCO₃ soln. and the mixture was extracted (2X) with EtOAc. The combined extracts were washed with NaHCO₃ soln., water and brine; dried (MgSO₄) and evaporated to a gum which was purified by column chromatography on silica (hexane/EtOAc; 0 – 100 %), giving the product as a white foam, 0.73 g (39 %).

MS (ES +ve) M+H = 506, M+Na = 528.

- 15 ¹H NMR (DMSO-d₆): 0.85 (9H, s), 2.29 (3H, d, J = 4.5 Hz), 2.74 (1H, dd, J = 13.5, 6 Hz), 2.93 (1H, dd, J = 13.5, 9.5 Hz), 3.13 (1H, m), 3.86 (1H, t, J = 7.5 Hz), 4.11 (1H, d, J = 9.5 Hz), 4.80 (2H, s), 5.71 (1H, d, J = 7.5 Hz), 7.29 – 7.48 (8H, m), 7.53 – 7.58 (2H, m), 7.61 (1H, s), 7.76 – 7.80 (2H, m), 7.85 (1H, d, J = 7 Hz), 11.27 (1H, s).


- 20 b) N'-[4-(N-Benzyloxyamino)-3S-tert-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



- 25 N'-[4-(N-Benzyloxyamino)-3S-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (0.69 g, 1.36 mmol) was dissolved in DCM (30 mL) and the solution cooled in an ice-salt bath. Into the cooled solution was condensed isobutylene (ca. 30 mL) by means of a cardice-acetone condenser. Conc. H₂SO₄ (12 drops) was added and the mixture was allowed to stir while warming to room temp overnight. The mixture was diluted with 3-4 times its volume of EtOAc and washed with NaHCO₃, water and brine; dried (MgSO₄) and evaporated to a gum which was purified by chromatography on silica (hexane/EtOAc; 0-100 %). The product was obtained as a white foam 0.31 g (41%).
- 30 MS (ES +ve) M+H = 562, M+Na = 584.

- ¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.10 (9H, s), 1.98 (3H, d, J = 4.5 Hz), 2.65 (1H, dd, J = 11, 4 Hz), 2.76 (1H, dd, J = 11, 11 Hz), 3.08 (1H, m), 3.94 (1H, d, J = 9 Hz), 4.02 (1H, d, J = 9 Hz), 4.81 (d, J = 13.5 Hz) and 4.86 (d, J = 13.5 Hz)(Abq), 6.93 (1H, br. q, J = 4.5 Hz), 7.22 (1H, d, J = 8.5 Hz), 7.30 - 7.47 (8H, m), 7.53 (1H, s), 7.73 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 8 Hz), 7.84 (1H, d, J = 8 Hz), 11.35 (1H, s).


- c) N'-[3S-tert-Butoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



- N'-[4-(N-benzyloxyamino)-3S-tert-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (0.305g, 0.54 mmol) was hydrogenated for 4 hr. at room temperature and atmospheric pressure in the presence of Pd-BaSO₄ (0.31 g). The catalyst was removed by filtration and the filtrate evaporated. The residue was triturated with ether to give the product as an off-white solid, 0.152 g (59 %).
- MS (ES +ve) M+H = 472, M+Na = 494.
- ¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.11 (9H, s), 1.93 (3H, d, J = 4.5 Hz), 2.70 (1H, dd, J ≈ 11, 4 Hz), 2.80 (1H, dd, J ≈ 11, 11 Hz), 3.11 (1H, m), 3.93 (1H, d, J = 9 Hz), 4.02 (1H, d, J = 9 Hz), 6.84 (1H, br. q, J = 4.5 Hz), 7.25 (1H, d, J = 8.5 Hz), 7.40 - 7.46 (3H, m), 7.56 (1H, s), 7.74 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J ≈ 8 Hz), 7.84 (1H, d, J ≈ 8 Hz), 8.96 (1H, s), 10.74 (1H, br. s).

Example 35

N'-[3S-tert-Butoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide




- N'-[4-(N-Benzyloxyamino)-3S-tert-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide was prepared and hydrogenolysed as described in example 34 to give the product as a slightly greyish solid, 0.224 g (88 %).

MS (ES +ve) M+H = 486, M+Na = 508.


¹H NMR (DMSO-d₆): 0.63 (3H, t, J = 7 Hz), 0.85 (9H, s), 1.12 (9H, s), 2.39 (1H, m), 2.55 (1H, m), 2.70 (1H, dd, J ≈ 11, 4 Hz), 2.81 (1H, dd, J ≈ 11, 11 Hz), 3.11 (1H, m), 3.92 (1H, d, J = 9 Hz), 4.02 (1H, d, J = 9 Hz), 7.05 (1H, br. t, J = 4.5 Hz), 7.26 (1H, dd, J = 8.5, 1.5 Hz), 7.40 - 7.46 (3H, m), 7.57 (1H, s), 7.73 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J ≈ 8 Hz), 7.82 (1H, d, J ≈ 8 Hz), 8.95 (1H, s), 10.73 (1H, br. s).

Example 36

10 N'-[4-(N-Hydroxyamino)-3S-(2-oxy-N-(N',N'-2-dimethylaminoethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



15 a) N'-[4-t-Butoxy-3S-(2-oxybenzylacetate)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




The title compound was prepared by alkylating N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl-S-tert-leucine methylamide with 2-bromo

20 benzylacetate in acetonitrile (c.f. example 1a).

MS (ES +ve) M+H = 605, M+Na = 629

¹H NMR (CDCl₃): 1.02 (9H, s), 1.42 (9H, s), 2.59 (3H, d, J = 5 Hz), 3.07-3.30 (3H, m), 3.77 (1H, d, J = 3.5 Hz), 3.98 (1H, d, J = 16 Hz), 4.12 (1H, d, J = 9 Hz), 4.35 (1H, d, J = 16 Hz), 5.26 (2H, s), 6.23 (1H, q, J = 4 Hz), 7.04 (1H, d, J = 9 Hz), 7.29-7.48 (8H, m), 7.64 (1H, s), 7.68-7.83 (3H, m).

b) N'-[4-t-Butoxy-3S-(2-oxyacetic acid)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



5

N'-[4-t-Butoxy-3S-(2-oxybenzylacetate)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (2.71g, 4.49 mmol) in methanol (70 ml) was hydrogenolyzed with Pd/ BaSO₄ (0.51g) at room temperature and atmospheric

10 pressure for 4 hours. The solution was filtered through Celite and concentrated to give 2.30g of a white solid (100%).


MS (ES +ve) M+H = 515

MS (ES -ve) M-H = 513

¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.44 (9H, s), 2.25 (3H, d, J = 7.2 Hz), 2.75-
15 3.03 (2H, m), 3.27 (1H, m), 3.96-4.13 (4H, m), 7.30 (1H, dd, J = 1.4, 8.4 Hz),
7.44 (3H, m), 7.74 (1H, s), 7.74-7.88 (4H, m), 12.65 (1H, s).

c) N''-[4-Butoxy-3S-(2-oxy-N-(N',N'-2-dimethylaminoethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide

20




N'-[4-t-Butoxy-3S-(2-oxyacetic acid)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (0.6g, 1.16 mmol), EDC (0.25g, 1.28 mmol) and HOAT
25 (0.17g, 1.28mmol) were stirred in DMF (11ml) under argon at room temperature for 10 minutes and then 2-(dimethylamino)ethylamine (0.15 ml, 1.40 mmol) was added. The reaction was stirred overnight under argon at room temperature. The DMF was evaporated and the residue partitioned between ethyl acetate and water. The organic layer was washed with water (x2), sodium bicarbonate solution (x2),

and brine, then dried (Na_2SO_4) and evaporated. Chromatography on silica gel (dichloromethane-methanol) gave the title compound (62%).

MS (ES +ve) $\text{M}+\text{H} = 585$

^1H NMR ($\text{DMSO}-d_6$): 0.83 (9H, s), 1.45 (9H, s), 2.18 (6H, s), 2.30 (3H, d, $J = 4.5$ Hz), 2.36 (2H, t, $J = 6.8$ Hz), 2.82-3.05 (2H, m), 3.19-3.40 (4H, m), 3.77 (1H, d, $J = 15.5$ Hz), 3.94 (1H, d, $J = 17.0$ Hz), 4.15 (1H, d, $J = 9.5$ Hz), 7.29 (1H, dd, $J = 1.5, 8.5$ Hz), 7.46 (2H, m), 7.59 (1H, s), 7.67 (1H, m), 7.75-7.86 (5H, m).

d) **N''-[4-(N-Hydroxyamino)-3S-(2-oxy-N-(N',N'-2-dimethylaminoethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide**



Cleavage of the tert-butyl ester and formation of the hydroxamic acid by coupling of the carboxylic acid with O-benzylhydroxylamine followed by hydrogenolysis with $\text{Pd}-\text{BaSO}_4$ gave the title compound.


MS (ES +ve) $\text{M}+\text{Na} = 556$, $\text{M}+\text{H} = 544$

MS (ES -ve) $\text{M}-\text{H} = 542$

^1H NMR ($\text{DMSO}-d_6$): 0.81 (9H, s), 2.20 (3H, d, $J = 4.5$ Hz), 2.74 (1H, dd, $J = 3.7, 13.6$ Hz), 2.82 (3H, s), 2.83 (3H, s), 2.89 (1H, d, $J = 13.7$ Hz), 3.14 (2H, d, $J = 5.2$ Hz), 3.33 (1H, td, $J = 4.0, 10.2$ Hz), 3.43 (2H, m), 3.82 (1H, d, $J = 15.5$ Hz), 3.93 (1H, d, $J = 15.5$ Hz), 3.97 (1H, d, $J = 9.6$ Hz), 4.11 (1H, d, $J = 9.5$ Hz), 7.22 (1H, dd, $J = 1.2, 8.4$ Hz), 7.45 (3H, m), 7.54 (1H, s), 7.74 (1H, d, $J = 8.5$ Hz), 7.77 (1H, d, $J = 7.5$ Hz), 7.84 (2H, d, $J = 8.7$ Hz), 8.00 (1H, t, $J = 5.7$ Hz), 9.29 (1H, s), 11.09 (1H, s).


Example 37

N'-[4-(N-Hydroxyamino)-3S-(2-oxy-N-(2'-acetoxyethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



5

a) N'-[4-Butoxy-3S-(2-oxy-N-(2-hydroxyethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



10


Reaction of 2-aminoethanol with N'-[4-t-Butoxy-3S-(2-oxyacetic acid)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide as for example 36c gave the title compound.

MS (ES +ve) M+Na = 580, M+H = 558

15 ¹H NMR (DMSO-d₆): 0.83 (9H, s), 1.45 (9H, s), 2.29 (3H, d, J = 4.5 Hz), 2.85 (1H, m), 2.95 (1H, m), 3.20 (2H, m), 3.32 (1H, m), 3.42 (2H, m), 3.78 (1H, d, J = 15.3 Hz), 3.94 (1H, d, J = 15.3 Hz), 3.98 (1H, d, J = 8.1 Hz), 4.15 (1H, d, J = 9.60 Hz), 4.68 (1H, t, J = 5.6 Hz), 7.28 (1H, dd, J = 1.6, 8.4 Hz), 7.45 (2H, m), 7.59 (1H, s), 7.68 (2H, m), 7.77 (2H, m).


20

b) N'-[4-Butoxy-3S-(2-oxy-N-(2-acetoxyethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



- 5 To a solution of N'-[4-Butoxy-3S-(2-oxy-N-(2-hydroxyethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (0.8g, 1.05mmol), pyridine (0.25ml, 3.15mmol) and DMAP (few crystals) in dichloromethane (8.5ml) at 0°C was added acetic anhydride. The mixture was stirred at 0°C for 1 hour and was then diluted with ethyl acetate and washed with dilute HCl (x2), NaHCO₃
- 10 solution and brine, dried (Na₂SO₄) and concentrated. Chromatography on silica gel (hexane/ ethyl acetate -1:4) gave 0.56g of product (88%).
- MS (ES +ve), M+H = 600
- ¹H NMR (DMSO-d₆): 0.82 (9H, s), 1.45 (9H, s), 1.99 (3H, s), 2.31 (3H, d, J = 4.5 Hz), 2.82-3.05 (2H, m), 3.31-3.40 (3H, m), 3.79 (1H, d, J = 15.5 Hz), 3.95 (1H, d, J = 6.3 Hz), 4.02 (1H, d, J = 16.4 Hz), 4.16 (1H, d, J = 9.6 Hz), 7.28 (1H, dd, J = 1.3, 8.3 Hz), 7.46 (2H, m), 7.59 (1H, s), 7.70-7.93 (6H, m).
- 15

- c) N'-[4-(N-Hydroxyamino)-3S-(2-oxy-N-(2'-acetoxyethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide
- 20




- 25 Removal of the tert-butyl ester from N'-[4-Butoxy-3S-(2-oxy-N-(2-acetoxyethyl)acetamido) -2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide with TFA, followed by coupling with hydroxylamine as described previously gave the title compound.
- MS (ES +ve) M+Na = 581, M+H = 559

¹H NMR (DMSO-d₆): 0.80 (9H, s), 2.01 (3H, s), 2.17 (3H, d, J = 4.5 Hz), 2.75 (1H, m), 2.88 (1H, m), 3.32 (3H, m), 3.70 (1H, d, J = 15.6 Hz), 3.90 (1H, d, J = 16.0 Hz), 3.94 (1H, d, J = 9.9 Hz), 4.03 (2H, t, J = 5.7 Hz), 4.13 (1H, d, J = 9.6 Hz), 7.22 (1H, dd, J = 1.3, 8.3 Hz), 7.43 (3H, m), 7.54 (1H, s), 7.72 (1H, d, J = 8.5 Hz), 7.76 (1H, d, J = 9.0 Hz), 7.83 (2H, m), 7.86 (1H, d, J = 9.7 Hz), 9.19 (1H, s), 11.07 (1H, s).

Example 38

N'-[4-(N-Hydroxyamino)-3S-N-(2-hydroxyethyl)carbamoylmethoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




N'-[4-(N-Hydroxyamino)-3S-(2-oxy-N-(2'-acetoxyethyl)acetamido)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (0.27g, 0.49 mmol) in dioxan (4.4 ml)/ water (3 ml) was stirred with LiOH.H₂O (0.062g, 1.47 mmol) at room temperature for two hours. Amberlite IR-120 (plus) resin was added until pH=4 and then the mixture was filtered, concentrated, azeotroped with toluene and dried under vacuum to give a white solid. Purification by preparative HPLC gave the title compound.



MS (ES +ve) M+Na = 539, M+H = 517

MS (ES -ve) M-H = 515

¹H NMR (DMSO-d₆): 0.81 (9H, s), 2.15 (3H, d, J = 4.5 Hz), 2.72 (1H, dd, J = 3.9, 13.5 Hz), 2.85 (1H, dd, J = 10.7, 13.5 Hz), 3.12 (1H, m), 3.21 (1H, m), 3.34 (1H, m), 3.42 (2H, t, J = 6.5 Hz), 3.69 (1H, d, J = 15.4 Hz), 3.87 (1H, d, J = 15.4 Hz), 3.93 (1H, d, J = 9.7 Hz), 4.12 (1H, d, J = 9.7 Hz), 7.23 (1H, dd, J = 1.5, 8.4 Hz), 7.45 (3H, m), 7.54 (1H, s), 7.61 (1H, t, J = 5.8 Hz), 7.72 (1H, d, J = 8.5 Hz), 7.77 (1H, d, J = 7.5 Hz), 7.82 (1H, d, J = 8.1 Hz), 7.89 (1H, d, J = 9.6 Hz), 9.30 (1H, s), 11.09 (1H, s).

Example 39**N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-3S-(2-oxyphenacyl)]-S-tert-leucine methylamide**

- 5 Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with phenacyl bromide instead of allyl bromide.
 MS (ES -ve) M-H = 532
¹H NMR (DMSO-d₆): 0.89 (9H,s), 2.5-2.53 (3H, obs), 3.20 (2H,d, J = 8 Hz),
 10 3.50-3.60 (1H,m), 3.83 (1H, d, J = 15 Hz), 3.91 (1H, d, J = 15), 4.19 (1H, d, J = 9 Hz), 4.21 (1H, d, J = 5 Hz), 6.89 (1H, s), 7.3-7.49 (8H, m), 7.76 (1H, s), 7.8-7.9 (4H, m), 7.97 (1H, br d, J = 9), 9.39 (1H, s).
- 15 **N'-[4-t-Butoxy-3S-(2RS-hydroxypropoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (A) and N'-[4-t-Butoxy-3S-(3-hydroxypropoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (B)**



- 20 **N'-[3S-Allyloxy-4-t-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide** (4.0g, 8.05mmol) and Wilkinson's catalyst (225mg) in THF (70ml) were cooled to 0°C and catechol borane (2.58ml, 24.2mmol) was added via syringe. The mixture was stirred at 0°C for 30 mins and then at room temperature for 1 hr and then 1:1 THF/ethanol (25ml), pH 7 phosphate buffer (25ml) and
 25 27.5% hydrogen peroxide solution (25ml) were added and the mixture was stirred at room temperature for 24hrs. The THF was evaporated and brine and ethyl acetate were added. The product was extracted into ethyl acetate and the extracts were washed with sodium carbonate solution and brine and then dried (Na₂SO₄) and concentrated. Purification by column chromatography on silica gel (ethyl
 30 acetate/ hexane) gave A) 0.627g (15%) and B) 1.958g (47%)
 A) MS ES +ve M+H = 515


¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.04 and 1.05 (3H, 2 x d, J = 6.0 Hz), 1.44 (9H, s), 2.24 and 2.26 (3H, 2 x d, J = 4.5 Hz), 2.84 (1H, dd, J = 5.0, 14.0 Hz), 2.96 (1H, m), 3.10-3.38 (3H, m), 3.69 (1H, m), 3.85 and 3.87 (1H, 2 x d, J = 8.0 Hz), 4.09 (1H, d, J = 9.5 Hz), 4.48 and 4.53 (1H, 2 x d, J = 4.5 Hz), 7.30 (1H, dd, J = 1.5, 8.5 Hz), 7.44 (3H, m), 7.61 (1H, s), 7.69-7.86 (4H, m).

B) MS ES +ve M+H = 515, M+Na = 537


¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.45 (9H, s), 1.63 (2H, m), 2.20 (3H, d, J = 4.5 Hz), 2.76 (1H, dd, J = 5.0, 13.5 Hz), 2.95 (1H, dd, J = 10.0, 13.5 Hz), 3.20 (1H, m), 3.32-3.55 (4H, m), 3.79 (1H, d, J = 8.5 Hz), 4.08 (1H, d, J = 9.5 Hz), 4.35 (1H, t, J = 5.0 Hz), 7.29 (1H, dd, J = 1.5, 8.5 Hz), 7.32 (1H, m), 7.44 (2H, m), 7.60 (1H, s), 7.70 (1H, d, J = 9.5 Hz), 7.74-7.84 (3H, m).

Example 40

15 N'-[3S-(3-Acetoxypropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



20 a) N'-[3S-(3-Acetoxypropoxy)-4-t-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




25 To a solution of the N'-[4-t-Butoxy-3S-(3-hydroxypropoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (193mg, 0.38mmol), pyridine (0.092ml, 1.14mmol) and DMAP (a few crystals) in dichloromethane (3ml) at 0°C was added acetic anhydride (0.053ml, 0.56mmol). The mixture was

stirred at room temperature for 1 hr and was then diluted with ethyl acetate and washed with 1N HCl (2x), NaHCO₃ solution and brine and then dried and concentrated to give 207mg of product.

¹H NMR (DMSO-d₆): 0.83 (9H, s), 1.45 (9H, s), 1.78 (2H, m), 1.99 (3H, s), 2.20

- 5 (3H, d, J = 4.5 Hz), 2.76 (1H, dd, J = 5.0, 14.0 Hz), 2.95 (1H, dd, J = 10.0, 14.0 Hz), 3.21 (1H, m), 3.39 (1H, m), 3.50 (1H, m), 3.82 (1H, d, J = 8.5 Hz), 4.05 (2H, m), 4.08 (1H, d, J = 9.5 Hz), 7.28 (1H, dd, J = 1.5, 8.5 Hz), 7.33 (1H, m), 7.44 (2H, m), 7.59 (1H, s), 7.71 (1H, d, J = 9.5 Hz), 7.75-7.85 (3H, m).

- 10 b) N'-[3S-(3-Acetoxypropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide



- 15 Prepared from N'-[3S-(3-Acetoxypropoxy)-4-t-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by TFA deprotection of the ester and coupling of the resultant acid with hydroxylamine to give the title compound.


MS ES -ve M-H = 514

MS ES +ve M+H = 516

- 20 ¹H NMR (DMSO-d₆): 0.82 (9H, s), 1.74 (2H, m), 1.99 (3H, s), 2.05 (3H, d, J = 4.5 Hz), 2.65 (1H, dd, J = 3.0, 13.5 Hz), 2.82 (1H, dd, J = 11.0, 13.5 Hz), 3.23 (1H, m), 3.29 (1H, m, partially obscured), 3.45 (1H, m), 3.79 (1H, d, J = 9.5 Hz), 3.96-4.04 (3H, m), 7.01 (1H, m), 7.25 (1H, dd, J = 1.5, 8.5 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.61 (1H, d, J = 8.5 Hz), 7.74 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.84 (1H, d, J = 7.5 Hz), 9.12 (1H, s), 10.91 (1H, s).
- 25

Example 41

N'-[4-(N-Hydroxyamino)-3S-(3-hydroxypropoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide



5

N'-[3S-(3-Acetoxypropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (115mg, 0.223 mmol) and LiOH.H₂O (28mg, 0.67mmol) were stirred in 1,4-dioxan (2ml)/water (1.5ml) at room temperature for 1hr. Amberlite resin-IR120 (plus) was added to lower the pH to 3-4 and the mixture was filtered and evaporated. The product was then azeotroped with toluene, triturated with ether and dried under high vacuum to give the product as a white solid (89mg).

MS ES -ve M-H = 472

MS ES +ve M+H = 474


¹H NMR (DMSO-d₆): 0.83 (9H, s), 1.59 (2H, m), 2.06 (3H, d, J = 4.5 Hz), 2.66 (1H, dd, J = 4.0, 13.5 Hz), 2.83 (1H, dd, J = 11.0, 13.5 Hz), 3.20 (1H, m), 3.24 (1H, m, partially obscured), 3.36-3.48 (3H, m), 3.76 (1H, d, J = 9.5 Hz), 4.02 (1H, d, J = 9.5 Hz), 4.35 (1H, br s, exchangeable with D₂O), 7.04 (1H, m), 7.25 (1H, d, J = 8.5 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.58 (1H, d, J = 8.5 Hz), 7.74 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.83 (1H, d, J = 7.5 Hz), 9.08 (1H, s), 10.91 (1H, s).

20


Example 42

N'-[3S-(3-Dimethylaminopropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide

25



a) N'-[4-t-Butoxy-3S-(3-dimethylaminopropoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



- 5 To a solution of the N'-[4-t-Butoxy-3S-(3-hydroxypropoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (800mg, 1.56mmol) and triethylamine (0.326ml, 2.34mmol) in dichloromethane (8ml) at 0°C was added methanesulfonyl chloride (0.145ml, 1.87mmol). The mixture was stirred for 40 mins and then was diluted with dichloromethane and washed with 2N HCl and
10 brine and then dried (Na₂SO₄) and concentrated to give the mesylate as a white foam (895mg, 97%).


- The mesylate (660mg) was stirred in ethanol (6ml) with dimethylamine (3ml) in a sealed vessel for 20 hrs. The solvents were evaporated and ethyl acetate and saturated sodium carbonate solution were added and the product was extracted
15 into ethyl acetate. The extracts were washed with brine, dried (Na₂SO₄) and evaporated. Filtration through a short column of silica gel (elution with dichloromethane/methanol) gave a white foam (520mg, 86%).

MS ES +ve M+H = 542

- ¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.44 (9H, s), 1.61 (2H, m), 2.11 (6H, s), 2.20
20 (3H, d, J = 4.5 Hz), 2.27 (2H, m), 2.76 (1H, dd, J = 4.5, 13.5 Hz), 2.95 (1H, dd, J = 10.0, 13.5 Hz), 3.19 (1H, m), 3.32 (1H, m, partially obscured), 3.46 (1H, m), 3.80 (1H, d, J = 8.5 Hz), 4.09 (1H, d, J = 9.5 Hz), 7.28 (1H, dd, J = 1.5, 8.5 Hz), 7.33 (1H, m), 7.44 (2H, m), 7.60 (1H, s), 7.69 (1H, d, J = 9.5 Hz), 7.75 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.84 (1H, d, J = 7.5 Hz).

25

b) N'-[3S-(3-Dimethylaminopropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



Removal of the t-butyl ester from N'-[4-t-Butoxy-3S-(3-dimethylaminopropoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide

with TFA, conversion of the TFA salt to the HCl salt and coupling with O-

- 5 benzyloxyamine and removal of the O-benzyl group by hydrogenolysis gave the title compound.

MS ES -ve M-H = 499


MS ES +ve M+H = 501

- ¹H NMR (DMSO-d₆): 0.83 (9H, s), 1.59 (2H, m), 2.09 (3H, d, J = 4.5 Hz), 2.14
10 (6H, s), 2.27 (2H, m), 2.74 (1H, dd, J = 4.0, 13.5 Hz), 2.85 (1H, dd, J = 11.0, 13.5 Hz), 3.19 (1H, m), 3.37 (2H, m, partially obscured), 3.76 (1H, d, J = 9.0 Hz), 4.05 (1H, d, J = 9.5 Hz), 7.12 (1H, m), 7.26 (1H, dd, J = 1.0, 8.5 Hz), 7.43 (2H, m), 7.56 (1H, d, J = 9.5 Hz), 7.57 (1H, s), 7.74 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.83 (1H, d, J = 7.5 Hz), 9.03 (1H, s), 11.25 (1H, broad s).

15

Example 43

N'-[3S-(2-RS-Acetoxypropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide



20

Prepared from N'-[4-t-butoxy-3S-(2RS-hydroxypropoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide as in Example 40.

MS ES -ve M-H = 514


- 25 MS ES +ve M+H = 516

- ¹H NMR (DMSO-d₆): approx. 2:1 mixture of diastereoisomers, 0.82 (9H, s), 1.11 and 1.12 (3H, 2 x d, J = 6.5 Hz), 1.96 and 1.97 (3H, 2 x s), 2.02 and 2.05 (3H, 2 x d, J = 4.5 Hz), 2.68 (1H, m), 2.80 (1H, m), 3.23-3.50 (3H, m), 3.86 (1H, m), 4.00 and 4.01 (1H, 2 x d, J = 9.5 Hz), 4.80 (1H, m), 7.0 (1H, m), 7.25 (1H, d, J = 8.5 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.61 (1H, m), 7.74 (1H, d, J = 8.5 Hz), 7.77-7.84
30 (2H, m), 9.12 and 9.14 (1H, 2 x s), 10.90 (1H, s).

Example 44

N'-[4-(N-Hydroxyamino)-3S-(2-RS-hydroxypropoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide

5



Prepared by cleavage of the acetate in N'-[3S-(2-RS-acetoxypropoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide with lithium hydroxide as in Example 41.

10


MS ES -ve M-H = 472

MS ES +ve M+H = 474

¹H NMR (DMSO-d₆): approx. 2:1 mixture of diastereoisomers, 0.83 (9H, s), 0.98 and 1.00 (3H, 2 x d, J = 6.5 Hz), 2.09 and 2.11 (3H, 2 x d, J = 4.5 Hz), 2.67-2.89 (2H, m), 3.08-3.29 (3H, m), 3.65 (1H, m), 3.83 and 3.84 (1H, 2 x d, J = 9.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 4.50 and 4.51 (1H, 2 x d, J = 4.5 Hz), 7.12 and 7.19 (1H, 2 x m), 7.25 (1H, m), 7.44 (2H, m), 7.57 (1H, s), 7.62 (1H, m), 7.74 (1H, d, J = 8.5 Hz), 7.77-7.84 (2H, m), 9.09 and 9.11 (1H, 2 x s), 10.86 and 10.90 (1H, s).

15

N'-[4-t-Butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



A mixture of the N'-[3S-Allyloxy-4-t-butoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide (2.0g, 4.03mmol), N-methylmorpholine N-oxide (520mg, 4.43mmol) and osmium tetroxide (0.8 ml of 2.5 % solution in t-butanol) in acetone (24ml), t-butanol (6ml) and water (6ml) was stirred at room temperature for 24 hrs. A few crystals of solid osmium tetroxide were added and the mixture was stirred for a further 24 hrs. The solvents were removed and the mixture was filtered through a short column of silica gel (ethyl acetate) to give the intermediate diol as a white foam (2.098g, 98%)

30

The diol and sodium periodate (973mg, 4.55mmol) in 1,4-dioxan (36ml)/water (12ml) were stirred at room temperature for 5 hrs. A further batch of sodium periodate (90mg) was added and stirring was continued for a further 1 hr. Sodium borohydride (757mg, 20mmol) was added and after stirring for 30 mins the reaction was quenched with saturated ammonium chloride solution and the solvents were removed. Ethyl acetate and 1N HCl were added and the product was extracted into ethyl acetate. The extracts were washed with sodium bicarbonate solution and brine and then dried (Na₂SO₄) and concentrated.


Chromatography on silica gel (80% ethyl acetate in hexane) gave the product as a white foam (1.63g, 82%).

MS ES +ve M+H = 501

¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.44 (9H, s), 2.25 (3H, d, J = 4.5 Hz), 2.82 (1H, dd, J = 5.0, 13.5 Hz), 2.96 (1H, dd, J = 10.0, 13.5 Hz), 3.20 (1H, m), 3.36 (1H, m), 3.46-3.54 (3H, m), 3.88 (1H, d, J = 8.0 Hz), 4.10 (1H, d, J = 9.5 Hz), 4.51 (1H, t, J = 5.5 Hz), 7.30 (1H, dd, J = 1.5, 8.5 Hz), 7.44 (3H, m), 7.61 (1H, s), 7.72-7.86 (4H, m).

Example 45

N'-[3S-(2-Acetoxyethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide



Prepared from N'-[4-t-Butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide in an analogous manner to that described above for Example 40.


MS ES -ve M-H = 500

MS ES +ve M+H = 502

¹H NMR (DMSO-d₆): 0.82 (9H, s), 1.99 (3H, s), 2.05 (3H, d, J = 4.5 Hz), 2.67 (1H, m), 2.82 (1H, dd, J = 11.0, 13.0 Hz), 3.26 (1H, m, partially obscured), 3.46 (1H, m), 3.59 (1H, m), 3.85 (1H, d, J = 9.5 Hz), 4.00-4.04 (3H, m), 7.02 (1H, m), 7.24 (1H, dd, J = 1.5, 8.5 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.63 (1H, d, J = 9.5 Hz), 7.74 (1H, d, J = 8.5 Hz), 7.77 (1H, d, J = 7.5 Hz), 7.83 (1H, d, J = 7.5 Hz), 9.14 (1H, s), 10.92 (1H, s).

Example 46

N'-[4-(N-Hydroxyamino)-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide



5

Prepared from N'-[3S-(2-Acetoxyethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by cleavage of the acetate with lithium hydroxide.

MS ES -ve M-H = 458

10 MS ES +ve M+H = 460


¹H NMR (DMSO-d₆): 0.83 (9H, s), 2.12 (3H, d, J = 4.5 Hz), 2.74 (1H, dd, J = 4.0, 13.5 Hz), 2.85 (1H, dd, J = 10.5, 13.5 Hz), 3.19 (1H, m), 3.29-3.43 (4H, m), 3.83 (1H, d, J = 9.0 Hz), 4.05 (1H, d, J = 9.5 Hz), 4.51 (1H, broad s, exchanges with D₂O), 7.19 (1H, m), 7.25 (1H, dd, J = 1.5, 8.5 Hz), 7.43 (2H, m), 7.57 (1H, s), 7.62 (1H, d, J = 9.5 Hz), 7.74 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.83 (1H, d, J = 7.5 Hz), 9.07 (1H, s), 10.96 (1H, broad s).

15


Example 47

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(2-N-succinimidylethoxy)succinyl]-S-tert-leucine methylamide

20




a) N'-[4-t-Butoxy-2R-(2-naphthylmethyl)-3S-(2-N-succinimidylethoxy)-succinyl]-S-tert-leucine methylamide



- 5 A mixture of N'-[4-t-Butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide (320mg, 0.64mmol), triphenylphosphine (336mg, 1.28mmol), DEAD (0.202ml, 1.28mmol) and succinimide (127mg, 1.28mmol), in THF (4ml) was stirred at room temperature overnight. The solvents were evaporated and the residue was chromatographed on silica gel
10 (elution with ethyl acetate/hexane) to give the title compound contaminated with a small amount of triphenylphosphine oxide which was removed at the next stage. MS ES +ve M+H = 582, M+Na = 604.

- 15 b) N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(2-N-succinimidylethoxy)succinyl]-S-tert-leucine methylamide



- 20 Cleavage of the t-butyl ester from N'-[4-t-Butoxy-2R-(2-naphthylmethyl)-3S-(2-N-succinimidylethoxy)-succinyl]-S-tert-leucine methylamide with TFA, followed by chromatography (to remove triphenylphosphine oxide) and conversion of the carboxylic acid to the hydroxamic acid using standard conditions gave the title compound.

MS ES -ve M-H = 539


- 25 MS ES +ve M+H = 541, M+Na = 563

¹H NMR (DMSO-d₆): 0.85 (9H, s), 2.06 (3H, d, J = 4.5 Hz), 2.60 (4H, s), 2.64 (1H, dd, J = 3.5, 13.5 Hz), 2.82 (1H, dd, J = 11.0, 13.5 Hz), 3.22 (1H, m), 3.27-3.50 (4H, m, partially obscured), 3.81 (1H, d, J = 9.5 Hz), 4.04 (1H, d, J = 9.5 Hz), 7.04 (1H, m), 7.23 (1H, dd, J = 1.5, 8.5 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.61

(1H, d, J = 9.5 Hz), 7.73 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.84 (1H, d, J = 7.5 Hz), 9.13 (1H, s), 10.92 (1H, s).

Example 48

- 5 **N'-[3S-(2-Dimethylaminoethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide**




- 10 Prepared from N'-[4-t-butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine methylamide in analogous fashion to Example 42.
MS ES -ve M-H = 485
MS ES +ve M+H = 487
¹H NMR (DMSO-d₆): 0.84 (9H, s), 2.10 (3H, d, J = 4.5 Hz), 2.14 (6H, s), 2.35
15 (2H, m), 2.74 (1H, dd, J = 4.0, 13.5 Hz), 2.86 (1H, dd, J = 10.5, 13.5 Hz), 3.22 (1H, m), 3.30-3.50 (2H, m, partially obscured), 3.80 (1H, d, J = 9.0 Hz), 4.04 (1H, d, J = 9.5 Hz), 7.12 (1H, m), 7.25 (1H, dd, J = 1.0, 8.5 Hz), 7.44 (2H, m), 7.56 (1H, d, J = 9.5 Hz), 7.58 (1H, s), 7.74 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 7.5 Hz), 7.84 (1H, d, J = 7.5 Hz), 9.06 (1H, s), 11.08 (1H, broad s).

20

Example 49

- N'-[3S-(2-Acetoxyethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide**




25

- Prepared from N'-[4-t-butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide in an analogous fashion to Example 40.
MS ES -ve M-H = 514
MS ES +ve M+H = 516, M+Na = 538
30 ¹H NMR (DMSO-d₆): 0.66 (3H, t, J = 7.0 Hz), 0.83 (9H, s), 1.99 (3H, s), 2.50-2.70 (3H, m, partially obscured), 2.84 (1H, m), 3.28 (1H, m, partially obscured),

3.47 (1H, m), 3.60 (1H, m), 3.85 (1H, d, $J = 9.5$ Hz), 4.01-4.04 (3H, m), 7.21 (1H, m), 7.25 (1H, dd, $J = 1.5, 8.5$ Hz), 7.43 (2H, m), 7.57 (1H, s), 7.63 (1H, d, $J = 8.5$ Hz), 7.72 (1H, d, $J = 8.5$ Hz), 7.75-7.85 (2H, m), 9.14 (1H, s), 10.93 (1H, s).

5 Example 50

N'-[4-(N-Hydroxyamino)-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide



Prepared via cleavage of the acetate from N'-[3S-(2-acetoxyethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide with lithium hydroxide


MS ES -ve M-H = 472

MS ES +ve M+H = 474

¹H NMR (DMSO-d₆): 0.71 (3H, t, $J = 7.0$ Hz), 0.84 (9H, s), 2.58-2.76 (3H, m), 2.86 (1H, m), 3.20 (1H, m), 3.29-3.44 (4H, m), 3.82 (1H, d, $J = 9.5$ Hz), 4.05 (1H, d, $J = 9.5$ Hz), 4.53 (1H, t, $J = 5.5$ Hz), 7.25 (1H, dd, $J = 1.5, 8.5$ Hz), 7.35 (1H, m), 7.43 (2H, t), 7.57 (1H, s), 7.61 (1H, d, $J = 9.5$ Hz), 7.73 (1H, d, $J = 8.5$ Hz), 7.77 (1H, d, $J = 7.5$ Hz), 7.83 (1H, d, $J = 7.5$ Hz), 9.09 (1H, s), 10.88 (1H, s).

20 Example 51

N'-[3S-(2-Dimethylaminoethoxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide



Prepared from N'-[4-t-butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide in analogous fashion to Example 42.

MS ES -ve M-H = 499


ES +ve M+H = 501

¹H NMR (DMSO-d₆): 0.70 (3H, t, $J = 7.0$ Hz), 0.85 (9H, s), 2.22 (6H, s), 2.45 (2H, m, partially obscured), 2.60-2.76 (3H, m), 2.87 (1H, dd, $J = 10.5, 13.0$ Hz), 2.24 (1H, m), 3.41 (1H, m), 3.49 (1H, m), 3.81 (1H, d, $J = 9.0$ Hz), 4.04 (1H, d, J


= 9.5 Hz), 7.26 (1H, dd, J = 1.0, 8.5 Hz), 7.30 (1H, s), 7.44 (2H, m), 7.56 (2H, m), 7.72 (1H, d, J = 8.5 Hz), 7.77 (1H, d, J = 7.5 Hz), 7.80 (1H, m), 9.08 (1H, s), 11.10 (1H, br s).

5 Example 52

N'-[4-(N-hydroxyamino)-3S-(2-(1-imidazolyl)ethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide




- 10 a) **N'-[4-t-Butoxy-3S-(2-(1-imidazolyl)ethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide**



- 15 A solution of the mesylate (456mg, 0.770mmol) prepared from N'-[4-t-butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide (analogously to Example 42) and imidazole (115mg, 1.69mmol) in DMF (10ml) was heated at 100°C for 7 hrs. The DMF was evaporated and ethyl acetate and sodium carbonate solution were added. The product was extracted into ethyl acetate and the extracts were washed with brine and then dried (Na₂SO₄) and
- 20 evaporated. Chromatography on silica gel (elution with dichloromethane/methanol) gave the title compound as a white foam (44%).
MS ES +ve M+H = 565
¹H NMR (DMSO-d₆): 0.80 (3H, t, J = 7.0 Hz), 0.86 (9H, s), 1.37 (9H, s), 2.70-2.85 (3H, m), 2.96 (1H, dd, J = 9.5, 13.0 Hz), 3.25 (1H, m), 3.57 (1H, m), 3.70 (1H, m), 3.80 (1H, d, J = 7.5 Hz), 4.04-4.20 (3H, m, including d at 4.12, J = 9.5 Hz), 6.90 (1H, s), 7.23 (1H, m), 7.26 (1H, s), 7.40-7.48 (3H, m), 7.62 (1H, m), 7.70 (1H, s), 7.74-7.85 (4H, m).

b) N'-[4-(N-Hydroxyamino)-3S-(2-(1-imidazolyl)ethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide



5

Removal of the t-butyl ester from N'-[4-t-Butoxy-3S-(2-(1-imidazolyl)ethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide with TFA, conversion of the TFA salt to the HCl salt and coupling with O-benzylhydroxylamine and removal of the O-benzyl group by hydrogenolysis gave the title compound.

10 MS ES-ve M-H = 522


MS ES +ve M+H = 524,

¹H NMR (DMSO-d₆): 0.67 (3H, t, J = 7.0 Hz), 0.82 (9H, s), 2.50-2.68 (3H, m), 2.84 (1H, dd, J = 11.0, 13.5 Hz), 3.32 (1H, m, partially obscured), 3.55 (1H, m), 3.65 (1H, m), 3.88 (1H, d, J = 9.5 Hz), 4.01-4.11 (3H, m), 6.87 (1H, s), 7.18 (1H, s), 7.19-7.26 (2H, m), 7.43 (2H, m), 7.55 (1H, s), 7.62 (1H, s), 7.71 (1H, d, J = 9.5 Hz), 7.73 (1H, d, J = 8.5 Hz), 7.77 (1H, d, J = 7.5 Hz), 7.80 (1H, d, J = 7.5 Hz), 9.15 (1H, s), 10.93 (1H, s).


20 **Example 53**

N'-[4-(N-Hydroxyamino)-3S-(2-methoxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide.

25



a) N'-[4-t-Butoxy-3S-(2-methoxyethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide



5

To a solution of N'-[4-t-Butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide (617mg, 1.2 mmol) and proton sponge (514mg, 2.4 mmol) in dichloromethane (10ml) was added trimethyloxonium tetrafluoroborate (355mg, 2.4mmol). After stirring at room temperature for 3 hrs, further quantities of proton sponge (130mg) and trimethyloxonium tetrafluoroborate (90mg) were added and the mixture was stirred for a further 2 hrs. Ethyl acetate and 2N HCl were added and the product was extracted into ethyl acetate. The extracts were washed with sodium bicarbonate solution and brine and then dried (MgSO₄) and concentrated. The product was chromatographed on silica gel (elution with ethyl acetate/hexane) to give the product as a white foam (88% yield).

15


MS ES +ve M+H = 529, M+Na = 551

¹H NMR (DMSO-d₆): 0.77 (3H, t, J = 7.2 Hz), 0.86 (9H, s), 1.44 (9H, s), 2.72-2.81 (3H, m), 2.97 (1H, dd, J = 10.0, 14.0 Hz), 3.22 (1H, m), 3.24 (3H, s), 3.41-3.47 (3H, m), 3.60 (1H, m), 3.86 (1H, d, J = 8.0 Hz), 4.09 (1H, d, J = 9.5 Hz), 7.29 (1H, dd, J = 8.5, 10.0 Hz), 7.40-7.55 (3H, m), 7.60 (1H, s), 7.70 (1H, d, J = 9.5 Hz), 7.75 (1H, d, J = 8.5 Hz), 7.77-7.85 (2H, m).

20

b) N'-[4-(N-Hydroxyamino)-3S-(2-methoxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine ethylamide

25



The t-butyl ester from N'-[4-t-Butoxy-3S-(2-methoxyethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine ethylamide was removed with TFA and

30

the resulting carboxylic acid was converted to the hydroxamic acid as above to give the title compound.

MS ES -ve M-H = 486


MS ES +ve M+H = 488, M+Na = 510

- 5 ¹H NMR (DMSO-d₆): 0.67 (3H, t, J = 7.5 Hz), 0.85 (9H, s), 2.50-2.69 (3H, m, partially obscured), 2.84 (1H, m), 3.20 (3H, s), 3.24 (1H, m), 3.39 (3H, m), 3.52 (1H, m), 3.80 (1H, d, J = 9.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 7.24 (2H, m), 7.43 (2H, m), 7.58 (2H, m), 7.72 (1H, d, J = 8.5 Hz), 7.75-7.85 (2H, m), 9.10 (1H, s), 10.90 (1H, s).

10

Example 54

N'-[3S-Ethoxy-4-(N-hydroxyamino)-2R-(2-benzothiophenylmethyl)succinyl]-S-tert-leucine methylamide



15

Prepared analogously to Example 1) a) + b) +c) from N-3S-Hydroxy-2R-4-methoxy- (2-benzothiophenylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with iododethane instead of allyl bromide.

- 20 MS (ES +ve) M+H = 450


- ¹H NMR (DMSO-d₆): 0.87 (9H, s), 1.04 (3H, t, J = 6.9 Hz), 2.23 (3H, d, J = 4.5 Hz), 2.71 (1H, td, J = 1.8 Hz, 15.6 Hz), 2.99 (1H, t, J = 15.6 Hz), 3.21 (2H, m), 3.43 (1H, m), 3.74 (1H, d, J = 9.5 Hz), 4.14 (1H, d, J = 9.5 Hz), 7.07 (1H, s), 7.28 (2H, m), 7.40 (1H, q, J = 4.6 Hz), 7.65 (1H, d, J = 7.3 Hz), 7.82 (2H, m), 9.10 (1H, s), 10.90 (1H, s).

25

Example 55

N'-[4-(N-Hydroxyamino)-3S-cyclohexyloxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide

30




Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with cyclohexenyl bromide (instead of allyl bromide), followed by hydrogenation.

5 MS (ES +ve) M+H = 498

¹H NMR (DMSO-d₆) 0.84 (9H, s), 1.10 (5H, m), 1.45 (1H, m), 1.64 (2H, m), 1.75 (1H, m), 1.84 (1H, m), 2.01(3H, d, J = 4.5 Hz), 2.67 (1H, J = 4, 13.5 Hz), 2.82 (1H, dd, J = 13.5, 11 Hz), 3.19 (2H, m), 3.97 (2H, m), 6.91 (1H, q, J = 4.5 Hz), 7.28 (1H, m), 7.43 (2H, m), 7.52 (1H, d, J = 9 Hz), 7.59 (1H, s), 7.79 (3H, m), 9.07(1H, s), 10.87(1H, s).

Example 56

15 N'-[4-(N-Hydroxyamino)-3S-(2-hydroxy-2-phenylethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




20 Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with phenacyl bromide instead of allyl bromide and reduction with triethylsilane and TFA.

MS (ES +ve) M+H = 536

¹H NMR (DMSO-d₆) 0.88 (9H, s), 2.19 (3H, d, J = 4.5 Hz), 2.82 (2H, m), 3.23 (1H, m), 3.40 (2H, d), 3.89 (1H, d, J = 9 Hz), 4.09 (1H, d, J = 9 Hz), 4.70 (1H, m), 5.32(1H, br.s), 7.28 (7H, m), 7.43 (2H, m), 7.54 (1H, s), 7.66 (1H, d), 7.78 (3H, m), 9.11 (1H, s), 10.86(1H, s).

Example 57

N'-[4-(N-Hydroxyamino)-3S-[2-(morpholin-4-yl)-2-oxoethoxy]-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



5

Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with N-(2-Bromoacetyl)morpholinamide instead of allyl bromide.

10 MS (ES +ve) M+H = 543


¹H NMR (DMSO-d₆) 0.80 (9H, s), 2.11 (3H, d, J = 4.5 Hz), 2.71 (1H, dd, J = 4,14 Hz), 2.87 (1H, dd, J = 11,14 Hz), 3.27-3.64 (9H, m), 3.91 (1H, d, J = 9 Hz), 3.96 (1H, d J = 12.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 4.13 (1H, d, J = 12.5 Hz), 7.19 (1H, q, J = 4.5 Hz), 7.26 (1H, m), 7.45 (2H, m), 7.58 (1H, s), 7.75 (4H, m), 9.14 (1H, s), 11.08 (1H, s).

15

Example 58

N'-[4-(N-Hydroxyamino)-3S-ethoxy-2R-(2-naphthylmethyl)succinyl]-S-(N,N-dimethyl lysine) methylamide

20




MS (ES +ve) M+H = 487

25 ¹H NMR (DMSO-d₆) 1.06 (3H, t, J = 7 Hz), 1.13 (1H, m), 1.30 (4H, m), 1.59 (1H, m), 1.84 (3H, d, J = 4.5 Hz), 2.08 (8H, m), 2.65 (1H, dd), 2.81 (1H, dd), 3.16 (1H, m), 3.30 (1H, m, partially obscured by water), 3.45 (1H, m), 3.78 (1H, d, J = 9.5 Hz), 4.00 (1H, m), 5.86 (1H, m), 7.29 (1H, m), 7.45 (2H, m), 7.64 (1H, s), 7.85 (3H, m), 7.98 (1H, d), 9.02 (1H, br.s), 11.00 (1H, br.s).

30

Example 59

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-(N,N-dimethyl-β,β-dimethyl-lysine) ethylamide




MS (ES +ve) M+H = 543

¹H NMR (DMSO-d₆) 0.66 (3H, t, J = 7 Hz), 0.84 (9H, m), 1.15 (2H, m), 1.35 (2H, m), 1.47 (2H, m), 2.07 (8H, m), 2.63 (2H, m), 2.84 (1H, dd, J = 11, 14 Hz), 3.16-3.40 (m, obscured by water), 3.76 (1H, d, J = 9.5 Hz), 4.08 (1H, d, J = 9.5 Hz), 7.26 (2H, m), 7.43 (2H, m), 7.52 (1H, d, J = 9.5 Hz), 7.57 (1H, s), 7.75 (3H, m), 9.14 (1H, v.br.s), 10.87 (1H, v.br.s).

Example 60

N'-[4-(N-Hydroxyamino)-3S-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethoxy]-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide



Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide by alkylation with N-(2-Bromoacetyl)-N'-methylpiperazinamide instead of allyl bromide.


MS (ES +ve) M+H = 556

¹H NMR (DMSO-d₆) 0.81 (9H, s), 2.11 (3H, d, J = 4.5 Hz), 2.17 (3H, s), 2.18-2.35 (4H, m), 2.72 (1H, dd, J = 4, 14 Hz), 2.88 (1H, dd, J = 11, 14 Hz), 3.27-3.52 (m, partially obscured by water), 3.91 (1H, d, J = 9.0 Hz), 3.96 (1H, d, J = 12.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 4.13 (1H, d, J = 12.5 Hz), 7.16 (1H, q, J = 4.5 Hz), 7.26 (1H, m), 7.44 (2H, m), 7.58 (1H, s), 7.65 (1H, d, J = 9.5 Hz), 7.70-7.86 (3H, m), 9.12 (1H, s), 11.09 (1H, s).

Example 61

N'-[4-(N-Hydroxyamino)-3S-ethoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine t-butylamide

5



Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine t-butylamide by alkylation with iodoethane instead of allyl bromide.

10


MS (ES +ve) M+H = 486

¹H NMR (DMSO-d₆): 0.84 (9H, s), 0.92 (9H, s), 1.05 (3H, t, J = 7 Hz), 2.62 (1H, dd, J = 3, 13.5 Hz), 2.85 (1H, dd, J = 13, 11.5 Hz), 3.19 (1H, m), 3.29 (1H, m obscured by water), 3.44 (1H, m), 3.75 (1H, d, J = 10 Hz), 4.08 (1H, d, J = 9.5 Hz), 7.07 (1H, s), 7.25 (1H, d, J = 8.5 Hz), 7.41 (2H, m), 7.48 (1H, d, J = 9.5 Hz), 7.56 (1H, s), 7.71 (1H, d, J = 8.5 Hz), 7.77 (2H, d, J = 8.5 Hz), 9.10 (1H, s), 10.92 (1H, s).

15

20 **Example 62**

N'-[4-(N-Hydroxyamino)-3S-allyloxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine t-butylamide



25 Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine t-butylamide by alkylation with allyl bromide.

MS (ES +ve) M+H = 498


¹H NMR (DMSO-d₆) 0.82 (9H, s), 0.92 (9H, s), 2.63 (1H, dd), 2.86 (1H, dd), 3.24 (1H, m), 3.79 (1H, dd), 3.82 (1H, d, J = 10 Hz), 3.94 (1H, dd), 4.07 (1H, d, obscured), 5.10 (1H, dd), 5.22 (1H, dd, J = 1.5, 17.5 Hz), 5.77 (1H, m), 7.07 (1H,

30

s), 7.25 (1H, dd), 7.41 (2H, m), 7.54 (2H, m), 7.71 (1H, d, $J = 8.5$ Hz), 7.78 (2H, dd, $J = 8.5$ Hz), 9.10 (1H, s), 10.93 (1H, s).

Example 63

- 5 **N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine t-butylamide**




- 10 Prepared analogously to Example 1) a) + b) +c) from N-4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine t-butylamide by alkylation with iodopropane instead of allyl bromide.
MS (ES +ve) $M+H = 500$
 ^1H NMR (DMSO- d_6) 0.82 (3H, t, $J = 7.5$ Hz), 0.84 (9H, s), 0.97 (9H, s), 1.45
15 (2H, m), 2.63 (1H, dd, $J = 3.5, 13.5$ Hz), 2.85 (1H, dd, $J = 11.5$ Hz), 3.18 (2H, m), 3.11 (1H, m, obscured by water), 3.75 (1H, d, $J = 9.5$ Hz), 4.07 (1H, m), 7.06 (1H, s), 7.25 (1H, d, $J = 8.5$ Hz), 7.44 (3H, m), 7.56 (1H, s), 7.72 (1H, d, $J = 8.5$ Hz), 7.78 (2H, d, 8.5 Hz), 9.09 (1H, s), 10.88 (1H, s).

20

Example 64

N'-[4-(N-Hydroxyamino)-3S-allyloxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine benzyl ester

25



- MS (ES +ve) $M+H = 533$
 ^1H NMR (DMSO- d_6) 0.81 (9H, s), 2.63 (1H, dd, $J = 3.5, 13.5$ Hz), 2.82 (1H, dd, $J = 13.5, 8$ Hz), 3.35 (1H, m), 3.76 (1H, dd, $J = 5.5, 13$ Hz), 3.84 (1H, d, $J = 10$ Hz), 3.93 (1H, dd, $J = 5, 13$ Hz), 4.18 (1H, d, $J = 9$ Hz), 4.42 (1H, d, $J = 12$ Hz), 4.59
30


(1H, d, J = 12.5 Hz), 5.08 (1H, d, J = 10.5 Hz), 5.20 (1H, d, J = 17 Hz), 5.74 (1H, m), 7.13 (2H, m), 7.23 (1H, d, J = 8.5 Hz), 7.29 (2H, m), 7.42 (2H, m), 7.57 (1H, s), 7.68 (1H, d, J = 8.5 Hz), 7.80 (2H, m), 8.05 (1H, d), 9.11 (1H, s), 10.98 (1H, s).

5

Example 65

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methoxyamide

10



MS (ES +ve) M+H = 474

¹H NMR (DMSO-d₆) 0.81 (3H, t, J = 7.5 Hz), 0.85 (9H, s), 1.44 (2H, m), 2.64


15 (1H, dd, J = 3.5, 13.5 Hz), 2.85 (1H, dd, J = 13.5, 11 Hz), 3.12 (1H, s), 3.20 (3H, m), 3.77 (1H, d, J = 9.5 Hz), 3.96 (1H, d, J = 9.5 Hz), 7.26 (1H, d, J = 8.5 Hz), 7.41 (2H, m), 7.56 (1H, s), 7.72 (1H, d, J = 8.5 Hz), 7.78 (3H, m), 9.09 (1H, s), 10.88 (1H, s), 10.94 (1H, s).

20

Example 66

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine (N,N-dimethylaminoeth-2-yl)amide

25



30 MS (ES +ve) M+H = 514


¹H NMR (DMSO-d₆) 0.82 (3H, t, J = 7.5 Hz), 0.84 (9H, s), 1.45 (2H, m), 2.01 (6H, s), 2.59 (1H, m), 2.64 (1H, dd), 2.74 (1H, m), 2.84 (1H, dd), 3.20 (2H, m), 3.77 (1H, d, J = 9.5 Hz), 4.05 (1H, d, J = 9.5 Hz), 7.23 (2H, m), 7.43 (2H, m), 7.58 (2H, m), 7.77 (3H, m), 9.10 (1H, s), 10.90 (1H, s).

5

Example 67

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-R-tert-leucine (N,N-dimethylaminoeth-2-yl)amide

10



15 MS (ES +ve) M+H = 514


¹H NMR (DMSO-d₆) 0.33 (9H, s), 0.76 (3H, t, J = 7.5 Hz), 1.37 (2H, m), 2.12 (6H, s), 2.70 (1H, dd), 2.77 (1H, dd, J = 13.5, 12 Hz), 3.10 (4H, m), 3.51 (1H, m), 3.72 (1H, d, J = 10 Hz), 4.00 (1H, d, J = 9.5 Hz), 7.35 (1H, d, J = 8.5 Hz), 7.41 (2H, m), 7.64 (1H, d, J = 9.5 Hz), 7.70 (1H, s), 7.77 (4H, m), 9.09 (1H, s), 10.92 (1H, s).

20

Example 68

N'-[4-(N-Hydroxyamino)-3S-ethoxy-2R-(2-naphthylmethyl)succinyl]-S-(O-benzyl) tert-leucinol

25




MS (ES +ve) M+H = 521

30 ¹H NMR (DMSO-d₆) 0.79 (9H, s), 0.82 (3H, t), 1.42 (2H, m), 2.63 (2H, m), 2.82 (2H, m), 3.19 (2H, m), 3.29 (1H, t), 3.64 (1H, m), 3.70 (2H, d, J = 7 Hz), 3.79

(1H, d, J = 10 Hz), 6.99 (1H, d, J = 6.5 Hz), 7.25 (4H, m), 7.42 (3H, m), 7.60 (1H, s), 7.68 (1H, d, J = 8.5 Hz), 7.79 (2H, m), 9.10 (1H, s), 10.97 (1H, s).


5 Example 69

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-[S-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl]succinyl]-S-tert-leucine methylamide



10

i) 2R-1,2,3,4-Tetrahydronaphthalene-2-methyl alcohol



15

2R-1,2,3,4-Tetrahydronaphthoic acid (2.26g, 12.84 mmol) (prepared as described by Charlton *et al*, Synlett. (1990), 333) in dry THF (35 ml) at 0-5°C was treated with a 1M soln. of LiAlH₄ in THF (12.85 ml) and the resulting mixture was stirred at 0-5°C for 0.25h followed by 1h at room temperature. The reaction mixture was then treated with water (1 ml), 2M NaOH soln. (1 ml) and water (1 ml) and then filtered through celite. The filtrate was evaporated to dryness and the residue partitioned between diethyl ether and dil. NaHCO₃ soln. The ether layer was separated, washed with dil NaHCO₃ soln. (x3) and brine (x1), and then dried over MgSO₄. It was filtered and evaporated to dryness. The crude product was purified by chromatography on silica gel to afford the title compound 1.51g.


20

25

¹H NMR (CDCl₃) 1.45 (2H, m), 1.97 (2H, m), 2.50 (1H, dd, J = 10.5, 16.5 Hz), 2.87 (3H, m), 3.64 (2H, br.s), 7.09 (4H, m).
[α] +88.2 (c = 0.53, CHCl₃)

30

ii) Trifluoromethane sulfonic acid [(R)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl] ester




35

The alcohol (1.47g, 9.07 mmol) and pyridine (0.72g, 9.07 mmol) in dry dichloromethane (20ml) were added dropwise to a solution of triflic anhydride (2.56g, 9.07 mmol) in dichloromethane at 0-5°C. The resulting mixture was stirred at that temperature for 2h before being washed with cold, dil. H₂SO₄ (x3),
 5 cold, dil. NaHCO₃ soln (x3) and brine (x1). The organic soln. was dried over MgSO₄, filtered and evaporated to yield the title compound as a golden oil (2.56g).

¹H NMR (CDCl₃) 1.55 (1H, m), 2.05 (1H, m), 2.35 (1H, m), 2.60 (1H, dd, J = 10.5, 16.5 Hz), 2.88 (3H, m), 4.48 (1H, d, J = 9.5 Hz), 4.53 (1H, d, J = 9.5 Hz),
 10 7.14 (4H, m).

iii) **Diethyl (2R,3S)-3-hydroxy-2-[(S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl] succinate**




15

S-Diethyl malate (2.94g, 15.3 mmol) in dry THF (25 ml) was added dropwise to a 1M soln. of LHMDs in THF (33.7 ml) at -70°C under argon keeping the temperature below -50°C during the addition. The solution was stirred at -70°C
 20 for 2h and then a solution of the above triflate (15.3 mmol) in dry THF (20 ml) was added slowly dropwise keeping the temperature below -60°C. The reaction solution was then stirred at -70°C to room temperature for 18h and then it was poured into cold, dilute HCl and the product was extracted with diethyl ether (x3). The combined extracts were washed with dil HCl (x1), satd. NaHCO₃ soln. (x3)
 25 and brine (x1) before being dried with MgSO₄, filtered and evaporated to leave the crude product. Chromatography on silica afforded the pure title compound (2.11g).

MS (ES +ve) M+Na = 357

¹H NMR (CDCl₃) 1.24 (3H, t, J = 7.0 Hz), 1.32 (3H, t, J = 7.0 Hz), 1.45 (1H, m),
 30 1.67 (1H, m), 1.83 (1H, m), 1.97 (1H, m), 2.45 (1H, dd, J = 10, 16 Hz), 2.82 (2H, m), 2.93 (1H, dd, J = 4, 16 Hz), 3.18 (1H, d, J = 7.5 Hz), 4.13 (2H, m), 4.27 (3H, m), 7.08 (4H, m).

iv) Diethyl (2R,3S)-3-allyloxy-2-[(S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl] succinate




5

The alcohol from (iii) above (1.62g, 4.85 mmol) and allyl bromide (5.87g, 48.5 mmol) in dry DMF (15 ml) were treated with 60% NaH in oil (0.233g, 5.82 mmol) and the mixture was stirred at room temperature for 1.25h. Satd. NH_4Cl soln. was then added and the mixture was evaporated to near dryness. The residue was partitioned between diethyl ether and water and the organic layer was separated and washed with dil HCl (x4) and brine (x1). The soln was dried (MgSO_4), filtered and evaporated to leave an orange oil. This was purified on silica to afford the title compound (1.61g).

MS (ES +ve) $\text{M}+\text{H} = 375$

15 ^1H NMR (CDCl_3) 1.26 (6H, m), 1.38 (2H, m), 1.71 (1H, m), 1.86 (2H, m), 2.37 (1H, dd), 2.79 (2H, m), 2.96 (1H, dd), 3.07 (1H, m), 3.93 (1H, dd, $J = 6, 12.5$ Hz), 4.07 (1H, d, $J = 8$ Hz), 4.17 (5H, m), 5.18 (1H, dd, $J = 1, 10.5$ Hz), 5.25 (1H, dd, $J = 1, 15.5$ Hz), 5.85 (1H, m), 7.07 (4H, m).

20 v) Diethyl (2R,3S)-3-propoxy-2-[(S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl] succinate




25 The O-allyl derivative from (iv) above (1.61g, 4.30 mmol) in methanol (30 ml) was hydrogenated at atmospheric pressure over 10% Pd/C (500mg) for 2h. The catalyst was filtered and the filtrate evaporated to dryness to afford the title compound as a colourless oil (1.56g).

MS (ES +ve) $\text{M}+\text{H} = 377$

30 ^1H NMR (CDCl_3) 0.89 (3H, t, $J = 7.5$ Hz), 1.26 (6H, m), 1.38 (2H, m), 1.58 (2H, m), 1.70 (1H, m), 1.83 (2H, m), 2.35 (1H, dd), 2.78 (2H, m), 2.95 (1H, dd), 3.03 (1H, m), 3.30 (1H, m), 3.53 (1H, m), 3.99 (1H, d, $J = 8.5$ Hz), 4.17 (4H, m), 7.06 (4H, m).

vi) (2R,3S)-3-Propoxy-2-[(S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl]succinic acid




- 5 The diethyl ester from (v) above (1.54g, 4.1 mmol) in dioxane (12 ml) was treated with 2M KOH soln. (6.15 ml) and the mixture was stirred at room temperature for 22.5h followed by 3h at 80°C. The soln. was evaporated to dryness and the resulting residue was dissolved in water and washed with ethyl acetate. The aqueous soln. was then saturated with NaCl and the pH adjusted to 1 with dil HCl.
- 10 The product was extracted into ethyl acetate (x3) and the combined extracts were washed with brine (x1), dried (MgSO₄), filtered and evaporated to afford the title compound as a white solid (1.35g).

MS (ES -ve) M-H = 319

- ¹H NMR (DMSO-d₆) 0.84 (3H, t, J = 7.5 Hz), 1.33 (2H, m), 1.47 (2H, m), 1.67 (2H, m), 1.82 (1H, m), 2.30 (1H, dd), 2.67-2.91 (4H, m), 3.25 (1H, m), 3.48 (1H, m), 3.85 (1H, d, J = 8 Hz), 7.05 (4H, m), 12.20-13.00 (2H, v.br.s).
- 15

vii) (2R,3S)-3-Propoxy-2-[(S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl]succinic acid 4-methyl ester


20



- The di-acid from (vi) above (1.3g, 4.1 mmol) in dry dichloromethane (15 ml) was cooled in an ice bath and treated with trifluoroacetic anhydride (8 ml). The resulting solution was stirred at 0-5°C for 10 mins followed by 2h at room temperature. The solution was then evaporated to dryness to leave the corresponding anhydride as a colourless oil (ν_{\max} 1788 cm⁻¹). This was dissolved in methanol (20 ml) and stirred at room temperature for 16 h. Evaporation of the solvent afforded the title compound as a pale yellow oil (1.43g).
- 25
- 30 MS (ES -ve) M-H = 333


¹H NMR (CDCl₃) 0.90 (3H, t, J = 7.5 Hz), 1.44 (2H, m), 1.62 (2H, m), 1.77-1.96 (3H, m), 2.40 (1H, dd), 2.80 (2H, m), 2.97 (1H, dd), 3.10 (1H, m), 3.34 (1H, m), 3.71 (1H, m), 3.76 (3H, s), 4.03 (1H, d, J = 7.5 Hz), 7.07 (4H, m).

- 5 **viii) N'-[4-Methoxy-3S-propoxy-2R-[S-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl)succinyl]-S-tert-leucine methylamide**



- 10 A solution of the acid from (vii) above (1.43g, 4.28 mmol) in dry DMF (15 ml) was treated with HOBt (1.16g, 8.56 mmol) and EDC (1.64g, 8.56 mmol) and the resulting soln. was stirred at room temperature for 10 mins. S-tert-leucine methylamide hydrochloride (0.85g, 4.71 mmol) was added followed by DIPEA (0.66g, 5.14 mmol) and the reaction solution was stirred at room
- 15 temperature for 1.25h. It was then evaporated to dryness and the residue was partitioned between EtOAc and dil. HCl. The organic layer was separated and washed with dil. HCl (x3), dil. NaHCO₃ (x3) and brine (x1). It was dried (MgSO₄) and evaporated to leave the crude product which was purified on silica to afford the title compound (1.44g).
- 20 MS (ES +ve) M+H = 461
- ¹H NMR (CDCl₃) 0.96 (3H, t, J = 7.5 Hz), 1.03 (9H, s), 1.32-1.74 (5H, m), 1.88 (2H, m), 2.42 (1H, dd), 2.73 (3H, d, J = 5 Hz), 2.76-3.00 (5H, m), 3.33 (1H, m), 3.62 (1H, m), 3.77 (3H, s), 3.99 (1H, d, J = 5 Hz), 4.09 (1H, d, J = 9 Hz), 6.29 (1H, m), 7.03 (5H, m).

- 25 **ix) N'-[4-Hydroxy-3S-propoxy-2R-[S-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl)succinyl]-S-tert-leucine methylamide**



- 30 A soln. of the ester from (viii) above (0.68g) in dioxane (12 ml) was treated dropwise with a soln. of LiOH.H₂O (0.124g) in water (5ml). The resulting soln. was stirred at room temperature for 1.75h and then it was evaporated to near

dryness. The residue was partitioned between water and EtOAc and the aqueous phase was separated and washed with EtOAc (x1) before being satd. with NaCl, acidified to pH 1, and extracted with EtOAc (x3). The combined extracts were washed with brine (x1), dried (MgSO₄) and evaporated to afford the product as a


5 white solid (0.63g).

MS (ES +ve) M+H = 447

¹H NMR (DMSO-d₆) 0.82 (3H, t, J = 7.5 Hz), 0.90 (9H, s), 1.22 (2H, m), 1.40-1.61 (4H, m), 1.73 (1H, m), 2.24 (1H, dd, J = 10, 16 Hz), 2.40 (3H, d, J = 4.5 Hz), 2.67 (2H, m), 2.95 (2H, m), 3.21 (1H, m), 3.38 (1H, m, obscured by water), 3.78
10 (1H, d, J = 9 Hz), 4.18 (1H, d, J = 9.5 Hz), 7.01 (4H, m), 7.71 (1H, q, J = 4.5 Hz), 7.90 (1H, d, J = 9.5 Hz), 12.84 (1H, br.s).

x) N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-[S-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl)succinyl]-S-tert-leucine methylamide

15



A soln. of the acid from (ix) above (0.61g) in dry DMF (10ml) was treated with HOAt (0.372g) and EDC (0.524g) and stirred at room temperature for 10 mins.


20 Hydroxylamine hydrochloride (0.285g) and NMM (0.414g) were then added and the reaction mixture was stirred at room temperature for 2h. It was then evaporated to dryness and the residue was partitioned between EtOAc and dil.HCl. The organic phase was separated and washed with dil HCl, dil. NaHCO₃ and water and then evaporated to dryness to leave a white solid. This was
25 triturated with diethyl ether then filtered and dried in vacuo to afford the title compound (0.434g).

MS (ES +ve) M+H = 462

¹H NMR (DMSO-d₆) 0.80 (3H, t, J = 7.5 Hz), 0.90 (9H, s), 1.08 (1H, m), 1.23 (1H, m), 1.45 (4H, m), 1.70 (1H, m), 2.19 (1H, dd), 2.35 (3H, d, J = 4.5 Hz), 2.65
30 (2H, m), 2.97 (2H, m), 3.14 (1H, m), 3.27 (1H, m), 3.63 (1H, d, J = 9.5 Hz), 4.18 (1H, d, J = 9.5 Hz), 7.02 (4H, m), 7.59 (1H, q, J = 4.5 Hz), 7.83 (1H, d, J = 9.5 Hz), 9.02 (1H, s), 10.78 (1H, s).

Example 70

N'-[3S-(Ethoxy)-4-(N-hydroxyamino)-2R-(2-quinolinylmethyl)succinyl]-S-tert-leucine ethylamide




- 5 5% Pd-BaSO₄ (50mg) was added to a solution of N'-[4-(N-Benzyloxyamino)-3S-(ethoxy)-2R-(2-quinolinylmethyl)succinyl]-S-tert-leucine ethylamide (0.17g, 0.3 mmol) in methanol (15 ml) and cyclohexene (5 ml) under argon. The mixture was heated at reflux for 6 hours then cooled and filtered through a celite plug. The filtrate was evaporated to give a solid which was triturated with ether (3 x 2 ml) to afford the title compound as a white solid (0.13g, 0.28 mmol, 92%).

MS (ES +ve) [M+H]⁺ = 459

- 1H NMR (DMSO-d₆): 0.66 (3H, t J = 7.2 Hz), 0.83 (9H, s), 1.04 (3H, t, J = 7.0 Hz), 2.58 (2H, m), 2.70 (1H, m), 2.84 (2H, m), 3.39 (2H, m), 3.81 (1H, d, J = 9.7 Hz), 4.05 (1H, d, J = 9.6 Hz), 7.35 (1H, t, J = 5.3 Hz), 7.55 (1H, t, J = 7.4 Hz), 7.68 (1H, d, J = 8.5 Hz), 7.70 (1H, d, J = 10.4 Hz), 7.83 (1H, d, J = 7.6 Hz), 7.94 (1H, d, 7.9 Hz), 7.97 (1H, s), 8.60 (1H, d, H = 2 Hz), 9.11 (1H, s), 10.96 (1H, s).

Example 71

- 20 **N'-[4-(N-Hydroxyamino)-3S-(propoxy)-2R-(2-quinolinylmethyl)succinyl]-S-tert-leucine ethylamide**



- 5% Pd-BaSO₄ (50mg) was added to a solution of N'-[4-(N-Benzyloxyamino)-3S-(propoxy)-2R-(2-quinolinylmethyl)succinyl]-S-tert-leucine ethylamide (0.12g, 0.21 mmol) in methanol (15 ml). The mixture was stirred under a hydrogen atmosphere for 48 hours then filtered through a celite plug. The filtrate was evaporated to give a solid which was triturated with ether (3 x 2 ml) to afford the title compound as a white solid (0.05g, 0.11 mmol, 54%).


MS (ES +ve) [M+H]⁺ = 473

- 1H NMR (DMSO-d₆): 0.66 (3H, t J = 7.2 Hz), 0.81 (3H, t, J = 7.0 Hz), 0.83 (9H, s), 1.43 (2H, m), 2.58 (2H, m), 2.70 (1H, m), 2.84 (2H, m), 3.39 (2H, m), 3.81 (1H, d, J = 9.7 Hz), 4.05 (1H, d, J = 9.6 Hz), 7.35 (1H, t, J = 5.3 Hz), 7.55 (1H, t, J = 7.4 Hz), 7.68 (1H, d, J = 8.5 Hz), 7.70 (1H, d, J = 10.4 Hz), 7.83 (1H, d, J =

7.6 Hz), 7.94 (1H, d, 7.9 Hz), 7.97 (1H, s), 8.60 (1H, d, H = 2 Hz), 9.11 (1H, s), 10.96 (1H, s).

5 Example 72


N'-[3S-(Ethoxy)-2R-(2-(6-fluoro)naphthylmethyl)-4-(N-hydroxyamino)succinyl]-S-tert-leucine ethylamide



- 10 5% Pd-BaSO₄ (50mg) was added to a solution of N'-[4-(N-Benzyloxyamino)-3S-(ethoxy)-2R-(2-(6-fluoro)naphthylmethyl)succinyl]-S-tert-leucine ethylamide (0.17g, 0.3 mmol) in methanol (15 ml) and cyclohexene (5 ml) under argon. The mixture was heated at reflux for 4 hours then cooled and filtered through a celite plug. The filtrate was evaporated to give a solid which was triturated with ether (3
- 15 x 2 ml) to afford the title compound as a white solid (0.12g, 0.26 mmol, 62%).
MS (ES +ve) [M+H]⁺ = 476
¹H NMR (DMSO-d₆): 1.04 (9H, s), 1.21 (3H, t, J = 7.0 Hz), 1.43 (3H, t, J = 6.6 Hz), 3.08 (2H, m), 3.41 (2H, m), 3.48 (2H, q, J = 7.0 Hz), 3.64 (1H, d, J = 2.8 Hz), 3.82 (1H, t, J = 7.2 Hz), 4.00 (1H, d, J = 9.1 Hz), 7.14 (1H, m), 7.22 (1H, m),
20 7.43 (2H, m), 7.71 (4H, m), 7.96 (1H, d, J = 10.5 Hz), 9.51 (1H, br s).

Example 73

- 25 **N'-[4-(N-Hydroxyamino)-3S-allyloxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methyl ester**




Prepared analogously to example 64.

- 30 MS (ES +ve) [M+H]⁺ = 445
¹H NMR (DMSO-d₆): 0.84 (9H, s), 1.01 (3H, t, J = 7 Hz), 2.68 (1H, dd, J = 13.5, 4 Hz), 2.73-2.83 (1H, m), 3.20-3.79 (3H, m), 3.27 (3H, s), 3.77 (1H, d, J = 10 Hz), 4.15 (1H, d, J = 9 Hz), 7.21 (1H, dd, J = 8, 1.5 Hz), 7.40-7.46 (2H, m), 7.55 (1H,

s), 7.74 (1H, d, J = 9 Hz), 7.75-7.81 (2H, m), 7.90 (1H, d, J = 9 Hz), 9.09 1H, d, J = 0.5 Hz), 10.96 (1H, d, J = 0.5 Hz).

5 Example 74

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-propoxy succinyl]-S-tert-leucine isopropylamide




- Prepared analogously to example 1 from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine isopropylamide by alkylation with allyl bromide, hydrogenation, tert butyl ester cleavage and hydroxamic acid formation.
- MS (ES -ve) $[M-H]^+ = 484$
- 1H NMR (DMSO- d_6): 0.72 (3H, d, J = 6.5 Hz), 0.75 (3H, d, J = 6.5 Hz), 0.82 (3H, t, J = 7.5 Hz), 0.84 (9H, s), 1.40-1.51 (2H, m), 2.64 (1H, dd, J = 13,3 Hz), 2.77-2.91 (1H, m), 3.18-3.37 (3H, m), 3.44-3.50 (1H, m), 3.77 (1H, d, J = 10 Hz), 4.06 (1H, d, J = 10 Hz), 7.24 (1H, dd, J = 8, 1.5 Hz), 7.36-7.44 (3H, m), 7.53 (1H, d, J = 10 Hz), 7.55 (1H, s), 7.70 (1H, d, J = 8.5 Hz), 7.72-7.79 (2H, m), 9.09 1H, s), 10.89 (1H, s).

20

Example 75


N'-[3S-Ethoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine isopropylamide



- Prepared analogously to example 1 from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine isopropylamide by alkylation with iodoethane, tert butyl ester cleavage and hydroxamic acid formation.
- MS (ES -ve) $[M-H]^+ = 470$
- 1H NMR (DMSO- d_6): 0.72 (3H, d, J = 6.5 Hz), 0.76 (3H, d, J = 6.5 Hz), 0.84 (9H, s), 1.05 (3H, t, J = 7 Hz), 2.63 (1H, dd, J = 13,3 Hz), 2.80-2.91 (1H, m), 3.17-3.27 (2H, m), 3.41-3.51 (2H, m), 3.76 (1H, d, J = 10 Hz), 4.08 (1H, d, J = 10 Hz), 7.24 (1H, dd, J = 8, 1.5 Hz), 7.39-7.44 (3H, m), 7.53 (1H, d, J = 10 Hz), 7.55 (1H, s), 7.69 (1H, d, J = 8 Hz), 7.71-7.78 (2H, m), 9.08 1H, s), 10.89 (1H, s).

Example 76

N'-[3S-Ethoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine (2,2,2-trifluoroethyl)amide



5

Prepared analogously to example 1 from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine-(2,2,2-trifluoroethyl)amide by alkylation with allyl bromide, hydrogenation, tert butyl ester cleavage and hydroxamic acid formation.

10 MS (ES -ve) $[M-H]^+ = 524$


1H NMR (DMSO- d_6): 0.81 (3H, t, $J = 7.5$ Hz), 0.83 (9H, s), 1.41-1.47 (2H, m), 2.62-2.67 (1H, m), 2.81 (1H, app t, $J = 13.5$ Hz), 3.17-3.80 (5H, m), 3.79 (1H, d, $J = 9.5$ Hz), 4.17 (1H, d, $J = 9.5$ Hz), 7.22 (1H, dd, $J = 10, 1.5$ Hz), 7.42-7.46 (2H, m), 7.53 (1H, s), 7.55 (1H, s), 7.63 (1H, d, $J = 9.5$ Hz), 7.72 (1H, d, $J = 8.5$ Hz), 7.76 (1H, d, $J = 8.5$ Hz), 7.83 (1H, d, $J = 8.5$ Hz), 8.06 (1H, app t, $J = 6$ Hz), 9.09 (1H, s), 10.92 (1H, s).

15

Example 77

N'-[3S-Ethoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine (2,2,2-trifluoroethyl)amide

20



Prepared analogously to example 1 from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine-(2,2,2-trifluoroethyl)amide by alkylation with allyl bromide, tert butyl ester cleavage and hydroxamic acid formation.


25 MS (ES -ve) $[M-H]^+ = 522$

1H NMR (DMSO- d_6): 0.81 (9H, s), 2.64-2.74 (2H, m), 3.24-3.31 (3H, m), 3.78 (1H, dd, $J = 8, 3.5$ Hz), 3.86 (1H, d, $J = 6$ Hz), 3.95 (1H, dd, $J = 8, 3.5$ Hz), 4.19 (1H, d, $J = 6$ Hz), 5.07-5.24 (2H, m), 5.74-5.81 (1H, m), 7.22 (1H, d, $J = 5$ Hz), 7.41-7.46 (2H, m), 7.53 (1H, s), 7.66-7.84 (4H, m), 8.12 (1H, t, $J = 4$ Hz), 9.11 (1H, s), 10.92 (1H, s).

30

Example 78


N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-[S or R-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl)succinyl]-S-tert-leucinamide



5 MS (ES -ve) $[M-H]^+ = 446$

Example 79

N'-[2R-(2-(6-Fluoronaphthyl)methyl)-4-(N-hydroxyamino)-3S-propoxy succinyl]-S-tert-leucine ethylamide



10

Prepared analogously to example 1 d) + e) from 2R-(2-(6-Fluoro)naphthylmethyl)-3S-hydroxy succinic acid diethyl ester, alkylating using allyl bromide.

15

MS (ES +ve) $M+H = 490$, $M+Na = 512$.


1H NMR (DMSO- d_6): 0.67 (3H, t, $J = 7$ Hz), 0.81 (3H, t, $J = 7.5$ Hz), 0.84 (9H, s), 1.45 (2H, sextet, $J = 7$ Hz), 2.53-2.68 (3H, m), 2.82 (1H, m), 3.16-3.25 (3H, m), 3.77 (1H, d, $J = 9.5$ Hz), 4.02 (1H, d, $J = 9.5$ Hz), 7.26-7.30 (2H, m), 7.35 (1H, m), 7.55-7.62 (2H, m), 7.61 (1H, s), 7.72 (1H, d, $J = 8.5$ Hz), 7.85 (1H, m), 9.09 (1H, br. s), 10.86 (1H, br. s).

20

Example 80

N'-[3S-Ethoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine cyclopropylamide

25



Prepared analogously to example 1 from N-[4-t-Butoxy-3S-(hydroxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine cyclopropylamide by alkylation with


allyl bromide, hydrogenation, tert butyl ester cleavage and hydroxamic acid formation.

MS (ES +ve) M+H = 470, M+Na = 492.

¹H NMR (DMSO-d₆): 0.06 (2H, m), 0.42 (2H, m), 0.83 (9H, s), 1.05 (3H, t, J = 7 Hz), 2.20 (1H, m), 2.63 (1H, dd, J = 14, 3.5 Hz), 2.87 (1H, dd, J = 14, 11 Hz), 3.19 (1H, m), ca. 3.28 & 3.44 (2H, 2 x m, partially obscured by H₂O signal), 3.76 (1H, d, J = 9.5 Hz), 4.05 (1H, d, J = 9.5 Hz), 7.23 (1H, dd, J = 8.5, 1.5 Hz), 7.42 (2H, m), 7.55 (1H, s), 7.59 (1H, d, J = 9.5 Hz), 7.72 (1H, d, J = 8.5 Hz), 7.80 (2H, m), 9.09 (1H, br. s), 10.88 (1H, br. s).

Example 81

N'-[3S-tert-Butoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucinamide




Prepared analogously to example 34.

MS (ES +ve) M+H = 458, M+Na = 480.

¹H NMR (DMSO-d₆): 0.90 (9H, s), 1.12 (9H, s), 2.73 (1H, dd, J = 14, 3.5 Hz), 2.90 (1H, dd, J = 14, 11 Hz), 3.04 (1H, m), 3.99 (1H, d, J = 9.5 Hz), 4.01 (1H, d, J = 9 Hz), 6.63 (1H, br. s), 6.83 (1H, br. s), 7.26 (1H, dd, J = 8.5, 1.5 Hz), 7.43 (2H, m), 7.55 (1H, d, J = 9 Hz), 7.59 (1H, s), 7.74 (1H, d, J = 8.5 Hz), 7.81 (2H, m), 8.95 (1H, br. s), 10.71 (1H, br. s).

Example 82

N'-[4-(N-Hydroxyamino)-3S-(1,2,4-oxadiazol-3-yl)methoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




MS (ES +ve) M+Na = 520, M+H = 498

MS (ES -ve) M-H = 496

¹H NMR (DMSO-d₆): 0.70 (9H, s), 2.04 (3H, d, J = 4.5 Hz), 2.67 (1H, m), 2.84 (1H, dd, J = 11.2, 13.6 Hz), 3.36 (1H, m), 3.98 (1H, d, J = 9.5 Hz), 4.04 (1H, d, J = 10.9 Hz), 4.48 (1H, d, J = 12.3 Hz), 4.63 (1H, d, J = 12.3 Hz), 6.99 (1H, q, J = 4.4 Hz), 7.24 (1H, d, J = 8.4 Hz), 7.44 (2H, m), 7.57 (1H, s), 7.63 (1H, d, J = 8.5 Hz), 7.73 (1H, d, J = 8.5 Hz), 7.78 (1H, d, J = 8.3 Hz), 7.84 (1H, d, J = 8.3 Hz), 9.20 (1H, s), 9.58 (1H, s), 11.05 (1H, s).

Example 83

N'-[4-(N-Hydroxyamino)-3S-(2-thiazolylmethoxy)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methylamide




MS (ES +ve) M+Na = 535, M+H = 512

MS (ES -ve) M-H = 511

¹H NMR (DMSO-d₆): 0.74 (9H, s), 2.04 (3H, d, J = 4.5 Hz), 2.70 (1H, m), 2.84 (1H, t, J = 13.5 Hz), 3.36 (1H, m), 4.01 (1H, d, J = 9.4 Hz), 4.07 (1H, d, J = 9.8 Hz), 4.65 (1H, d, J = 12.9 Hz), 4.77 (1H, d, J = 12.8 Hz), 7.04 (1H, d, J = 4.7 Hz), 7.27 (1H, d, J = 8.4 Hz), 7.44 (2H, m), 7.58 (1H, s), 7.74 (4H, m), 7.78 (1H, d, J = 8.3 Hz), 7.83 (1H, d, J = 8.3 Hz), 9.20 (1H, s), 11.05 (1H, s).

Example 84

N'-[2R-(4-Benzocycloheptyl)methyl-4-(N-hydroxyamino)-3S-(propoxy)succinyl]-S-tert-leucine methylamide



MS (ES +ve) M+H = 476, M+Na = 498


MS (ES -ve) M-H = 474

¹H NMR (DMSO-d₆): 0.79 (3H, t, J = 7.3 Hz), 0.93 (9H, s), 1.32-1.45 (3H, m), 1.70 (1H, m), 2.05 (1H, m), 2.45-2.56 (4H, m), 2.58-2.67 (7H, m), 2.91 (1H, m),

3.11 (1H, m), 3.26 (1H, m), 3.59. (1H, d, J = 9.6 Hz), 4.24 (1H, d, J = 9.5 Hz), 7.04 (4H, m), 7.76 (1H, d, J = 9.5 Hz), 7.82 (1H, d, J = 4.5 Hz), 8.97 (1H, s), 10.72 (1H, s).

5 Example 85

N'-[2R-(3-Benzocyclopentyl)methyl-4-(N-hydroxyamino)-3S-(propoxy)succinyl]-S-tert-leucine methylamide



10


MS (ES +ve) M+H = 448, M+Na = 470

MS (ES -ve) M-H = 446

¹H NMR (DMSO-d₆): 0.79 (3H, t, J = 7.4 Hz), 0.92 (9H, s), 1.25 (1H, m), 1.42 (2H, m), 1.56 (1H, m), 2.20 (1H, m), 2.34 (1H, m), 2.50 (4H, m), 2.88 (2H, m), 3.00 (1H, m), 3.13 (1H, m), 3.27 (1H, m), 3.63. (1H, d, J = 9.8 Hz), 4.23 (1H, d, J = 9.5 Hz), 7.06 (3H, m), 7.14 (1H, d, J = 3.6 Hz), 7.83 (2H, m), 9.00 (1H, s), 10.78 (1H, s).

20 Example 86

N'-[2R-(3-Benzocyclopentyl)methyl-4-(N-hydroxyamino)-3S-(propoxy)succinyl]-S-tert-leucine methoxyamide



25

MS (ES +ve) M+H = 464, M+Na = 486


MS (ES -ve) M-H = 462

¹H NMR (DMSO-d₆): 0.78 (3H, t, J = 7.4 Hz), 0.94 (9H, s), 1.23 (1H, m), 1.41 (2H, m), 1.55 (1H, m), 2.20 (1H, m), 2.36 (1H, m), 2.47 (1H, m), 2.88 (1H, m), 2.93-3.08 (2H, m), 3.12 (1H, m), 3.26 (1H, m), 3.45 (3H, s), 3.63 (1H, d, J = 9.9 Hz), 4.09 (1H, d, J = 9.4 Hz), 7.05 (3H, m), 7.14 (1H, m), 8.01 (1H, d, J = 9.4 Hz), 9.00 (1H, s), 10.79 (1H, s), 11.23 (1H, s).

30

Example 87

N'-[3S-(Allyloxy)-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-(S-(4-methoxybenzyl)penicillamide




MS (ES +ve) M+H = 580, M+Na = 602

10 MS (ES -ve) M-H = 578


¹H NMR (DMSO-d₆): 1.28 (3H, s), 1.29 (3H, s), 2.67 (2H, m), 2.95 (1H, m), 3.24 (1H, m), 3.68-3.86 (6H, m), 3.95 (1H, m), 4.49 (1H, d, J = 9.4 Hz), 5.07 (1H, dd, J = 1.6 Hz, 10.5 Hz), 5.20 (1H, dd, J = 1.7 Hz, 17.4 Hz), 5.78 (1H, m), 6.82 (2H, d, J = 8.7 Hz), 6.93 (1H, s), 7.21 (2H, d, J = 8.6 Hz), 7.27 (1H, d, J = 8.7 Hz), 7.34 (1H, s), 7.45 (2H, m), 7.60 (1H, s), 7.74 (1H, d, J = 8.5 Hz), 7.81 (2H, t, J = 8.4 Hz), 7.90 (1H, d, J = 8.7 Hz), 9.10 (1H, s), 10.95 (1H, s).

Example 88

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(2-*i*-propoxyethoxy)succinyl]-S-tert-leucine ethylamide.



a) N'-[4-t-Butoxy-2R-(2-naphthylmethyl)-3S-(2-i-propoxyethoxy)succinyl]-S-tert-leucine ethylamide.




5

To a solution of N'-[4-t-butoxy-3S-(2-hydroxyethoxy)-2R-(2-naphthylmethyl)-succinyl]-S-tert-leucine-N-ethylamide (220mg, 0.428 mmol) and proton sponge (128mg, 0.600 mmol) in dichloromethane (2 ml) was added methyltriisopropoxyphosphonium tetrafluoroborate (155mg, 0.566mmol). After stirring at room temperature for 3 days, further quantities of proton sponge (128mg) and methyltriisopropoxyphosphonium tetrafluoroborate (155mg) were added and the mixture was stirred for a further 24 hrs before addition of further batches of proton sponge (128mg) and methyltriisopropoxyphosphonium tetrafluoroborate (155mg). After stirring for a further 48 hrs, ethyl acetate and 2N HCl were added and the product was extracted into ethyl acetate. The extracts were washed with sodium bicarbonate solution and brine and then dried (MgSO₄) and concentrated. The product was chromatographed on silica gel (elution with ethyl acetate/hexane) to give the product as a gum (141mg, 59% yield).

MS ES +ve M+H = 557, M+Na = 579
¹H NMR (DMSO-d₆): 0.77 (3H, t, J = 7.5 Hz), 0.86 (9H, s), 1.07 (3H, d, J = 6.0 Hz), 1.08 (3H, d, J = 6.0 Hz), 1.44 (9H, s), 2.71-2.83 (3H, m), 2.97 (1H, dd, J = 10.0, 14.0 Hz), 3.22 (1H, m), 3.26-3.48 (3H, m), 3.53-3.62 (2H, m), 3.85 (1H, d, J = 8.0 Hz), 4.09 (1H, d, J = 9.5 Hz), 7.31 (1H, dd, J = 1.5, 8.5, Hz), 7.40-7.51 (3H, m), 7.63 (1H, s), 7.70 (1H, d, J = 9.5 Hz), 7.75 (1H, d, J = 8.5 Hz), 7.76-7.85 (2H, m).

25

b) N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(2-i-propoxyethoxy)-succinyl]-S-tert-leucine ethylamide.



30

The t-butyl ester was removed with TFA and the resulting carboxylic acid was converted to the hydroxamic acid as above to give the title compound.


MS ES -ve M-H = 514

5 MS ES +ve M+H = 516

¹H NMR (DMSO-d₆): 0.68 (3H, t, J = 7.0 Hz), 0.85 (9H, s), 1.06 (6H, d, J = 6.0 Hz), 2.50-2.75 (3H, m, partially obscured), 2.85 (1H, m), 3.24 (1H, m), 3.39 (3H, m), 3.45-3.55 (2H, m), 3.80 (1H, d, J = 9.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 7.26 (2H, m), 7.43 (2H, m), 7.58 (2H, m), 7.72 (1H, d, J = 8.5 Hz), 7.75-7.85 (2H, m),
10 9.09 (1H, s), 10.84 (1H, s).

Example 89

15 N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-[(3R,S-chroman-3-yl)methyl]succinyl]-S-tert-leucine methylamide




MS (ES +ve) M+H = 464

20 ¹H NMR (DMSO-d₆): 0.79 (3H, m), 0.91 (9H, s), 1.08 (1H, m), 1.40 (3H, m), 1.77 (1H, m), 2.30 (1H, m), 2.39 (1.5H, d), 2.49 (1.5H, d, obscured by DMSO), 2.68 (0.5H, m), 2.98 (1.5H, m), 3.13 (1H, m), 3.28 (1H, m), 3.61 (1.5H, m), 4.01 (0.5H, br.d), 4.19 (2H, m), 6.66 (1H, m), 6.78 (1H, m), 7.00 (2H, m), 7.65 (0.5H, m), 7.76 (0.5H, m), 7.91 (0.5H, d), 7.99 (0.5H, d), 9.02 (1H, s), 10.80 (1H, s).

25

Example 90

30 N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-(propoxy)-succinyl]-S-tert-leucine phenoxyamide




MS (ES -ve) M-H = 534

¹H NMR (DMSO-d₆): 0.84 (3H, t, J = 7.4 Hz), 0.95 (9H, s), 1.46 (2H, m), 2.66 (1H, m), 2.96 (1H, m), 3.20 (1H, m), 3.34 (2H, m), 3.78 (1H, d, J = 9.6 Hz), 4.22 (1H, d, J = 8.8 Hz), 6.88 (2H, d, J = 8.0 Hz), 6.95 (1H, m), 7.16 (2H, t, J = 7.8 Hz), 7.26 (1H, d, J = 8.4 Hz), 7.40 (2H, m), 7.58 (1H, s), 7.68 (2H, m), 7.80 (1H, m), 8.01 (1H, d, J = 9.5 Hz), 9.10 (1H, s), 10.92 (1H, s), 11.92 (1H, s).

Example 91

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine N-ethoxyamide




MS (ES +ve) M+H = 488

¹H NMR (DMSO-d₆): 0.83 (15H, m), 1.44 (2H, m), 2.63 (1H, dd, J = 3.5, 13.5 Hz), 2.84 (1H, dd, J = 11, 13.5 Hz), 3.25 (5H, m), 3.77 (1H, d, J = 6.5 Hz), 3.98 (1H, d, J = 9.5 Hz), 7.26 (1H, dd, J = 1.0, 8.5 Hz), 7.42 (2H, m), 7.70 (1H, s), 7.75 (4H, m), 9.09 (1H, s), 10.78 (1H, s), 10.88 (1H, s).

Example 92

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine N-isopropoxyamide




MS (ES +ve) M+H = 502

¹H NMR (DMSO-d₆) 0.85 (18H, m), 1.45 (2H, m), 2.64 (1H, dd, J = 3, 13.5 Hz), 2.87 (1H, dd, J = 11, 13.5 Hz), 3.19 (1H, m), 3.30 (2H, m), 3.48 (1H, m), 3.76 (1H, d, J = 9.5 Hz), 4.03 (1H, d, J = 9.5 Hz), 7.26 (1H, dd, J = 1.5, 8.4 Hz), 7.42 (2H, m), 7.57 (1H, s), 7.76 (4H, m), 9.09 (1H, s), 10.63 (1H, s), 10.90 (1H, s).

Example 93

N'-[4-(N-Hydroxyamino)-2R-(2-naphthylmethyl)-3S-propoxysuccinyl]-S-tert-leucine N,N-dimethylhydrazide



5


MS (ES +ve) M+H = 487

MS(ES -ve) M-H = 485, M+TFA = 599

¹H NMR (DMSO-d₆): 0.81 (3H, t, J = 7.4 Hz), 0.85 (9H, s), 1.45 (2H, m), 2.21 (6H, s), 2.66 (1H, m), 2.84(1H, s), 3.19 (1H, m), 3.32 (2H, m), 3.76(1H, d, J = 9.6 Hz), 3.99 (1H, d, J = 9.3 Hz), 7.26. (1H, d, J = 8.4 Hz), 7.43 (3H, m), 7.56 (1H, s), 7.70 (2H, m), 7.78 (2H, m), 9.22 (1H, s), 10.88 (1H, s).

15 **Example 94**

N'-[3S-tert-Butoxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine cyclopropylamide



20 The title product was prepared as previously described (e.g. Example 80) and crystallised from Et₂O/EtOAc/MeOH, to give a cream solid, 0.276 g (76 %).

MS (ES +ve) M+H = 498, M+Na = 520.


¹H NMR (DMSO-d₆): 0.05 (2H, m), 0.38 (2H, m), 0.83 (9H, s), 1.12 (9H, s), 2.10 (1H, m), 2.70 (1H, dd, J = 14, 3.5 Hz), 2.84 (1H, dd, J = 14, 11 Hz), 3.05 (1H, m), 3.94 (1H, d, J = 9.0 Hz), 4.01 (1H, d, J = 9.0 Hz), 7.24 (1H, dd, J = 8.5, 1.5 Hz), 7.38-7.47 (4H, m), 7.55 (1H, s), 7.73 (1H, d, J = 8.5 Hz), 7.80 (2H, m), 8.94 (1H, br. s), 10.69 (1H, br. s).

25

Example 95

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2R,S-(1,2,3,4-tetrahydronaphthyl)methyl)succinyl]-S-tert-leucine methoxyamide

5



The title product was prepared analogously to Examples 10 and 65 from diethyl (2R,3S)-3-hydroxy-2-[(R/S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl] succinate and the final compound triturated with Et₂O, to give a pale buff solid,


10 0.396 g (83 %).

MS (ES +ve) M+H = 478, M+Na = 500.

Example 96

N'-[4-(N-Hydroxyamino)-3S-isopropoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine methoxyamide

15



The title product was prepared analogously to Example 65 (alkylating N-[4-t-Butoxy-3S-hydroxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine benzyl ester with ⁱPrOTf) and triturating the final compound with Et₂O/EtOAc), to give a cream solid, 0.321g (69 %).

20

MS (ES +ve) M+H = 474, M+Na = 496.


¹H NMR (DMSO-d₆): 0.86 (9H, s), 1.00 (3H, d, J = 6 Hz), 1.04 (3H, d, J = 6 Hz), 2.64 (1H, dd, J = 14, 3.5 Hz), 2.86 (1H, dd, J = 14, 11 Hz), 3.12 (3H, s), 3.22 (1H, m), 3.51 (1H, m), 3.89 (1H, d, J = 9.5 Hz), 3.96 (1H, d, J = 9.5 Hz), 7.27 (1H, dd, J = 8.5, 1.5 Hz), 7.41 (3H, m), 7.56 (1H, s), 7.71 (2H, m), 7.78 (2H, apparent d, J = 9 Hz), 9.08 (1H, s), 10.89 (1H, s), 10.92 (1H, s).

25

Example 97

N'-[4-(N-Hydroxyamino)-3S-propoxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine N-tert-butoxyamide

5




MS (ES +ve) M+H = 516

¹H NMR (DMSO-d₆): 0.82 (3H, t, J = 7.5 Hz), 0.86 (9H, s), 0.87 (9H, s), 1.45 (2H, m), 2.62 (1H, dd, J = 3.5, 13.5 Hz), 2.90 (1H, dd, J = 11, 13.5 Hz), 3.26 (3H, m), 3.75 (1H, d, J = 9.5 Hz), 4.12 (1H, d, J = 9.5 Hz), 7.24 (1H, m), 7.41 (2H, m), 7.55 (1H, s), 7.71 (2H, m), 7.78 (2H, m), 9.08 (1H, s), 10.14 (1H, s), 10.89 (1H, s).

Example 98


N'-[3S-tert-Butoxy-4-(N-hydroxyamino) 2R-(2R,S-(1,2,3,4-tetrahydronaphthyl) methyl)succinyl]-S-tert-leucinamide



The title product was prepared analogously to Examples 10 and 81 from diethyl (2R,3S)-3-hydroxy-2-[(R,S)-1-(1,2,3,4-tetrahydronaphthalen-2-yl)methyl] succinate.

MS (ES +ve) M+H = 462, M+Na = 484.

25

Example 99**N'-[4-(N-Hydroxyamino)-2R-(5-methylbenzo[6]thiophene)-3S-propoxy-succinyl]-N-methyl-S-tert-leucinamide**


- 5 A solution of N'-[4-Hydroxy-2R-(5-methylbenzo[6]thiophene)-3S-propoxy-succinyl]-N-methyl-S-tert-leucinamide (60mg, 0.13 mmol) in anhydrous DMF (5ml) was treated sequentially with HOAT (36mg, 0.27 mmol) and EDC (51mg, 0.27 mmol), and the reaction solution was stirred at room temperature for 0.25h.
- 10 Hydroxylamine hydrochloride (28mg, 0.40 mmol) and N-methylmorpholine (0.04 ml, 0.40 mmol) were then added and the reaction solution was stirred for 3h at room temperature. The reaction solution was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The phases were separated and the organic phase was washed with further water and satd. sodium bicarbonate solution and dried with brine and over magnesium sulfate. The
- 15 organic phase was then evaporated and triturated with diethyl ether to give the hydroxamic acid as a white solid (15mg, 24%).

MS (ES +ve) $[M-H]^+ = 463$

- 1H NMR (DMSO- d_6): 0.89 (9H, s), 0.91 (3H, t, $J = 7.0$ Hz), 1.57 (2H, m), 2.24 (3H, d, $J = 4.9$ Hz), 2.82 (2H, m), 3.07 (1H, m), 3.31 (2H, m), 3.84 (1H, d, $J = 9.7$ Hz), 4.05 (1H, s), 7.14 (1H, d, $J = 5.3$ Hz), 7.22 (1H, q, $J = 5.6$ Hz), 7.27 (1H, d, $J = 3.4$ Hz), 7.50 (1H, d, $J = 3.4$ Hz), 7.53 (1H, t, $J = 6.0$ Hz), 7.59 (1H, s), 7.75 (1H, d, $J = 5.3$ Hz), 9.11 (1H, s), 10.96 (1H, s).
- 20

Example 100

- 25 **N'-[4-(N-Hydroxyamino)-3S-cyclohexyloxy-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine N-methoxyamide**



- 30 MS (ES +ve) $M+H = 514$

¹H NMR (DMSO-d₆) 0.86 (9H, s), 1.00-1.22 (5H, m), 1.45 (1H, m), 1.63 (2H, m), 1.76 (1H, m), 1.87 (1H, m), 2.67 (1H, J = 3.5, 13.5 Hz), 2.85 (1H, dd, J = 13.5, 11 Hz), 3.13 (3H, s), 3.21 (2H, m), 3.95 (2H, m), 7.28 (1H, m), 7.41 (2H, m), 7.56 (1H, s), 7.72 (2H, m), 7.78 (2H, m), 9.07 (1H, s), 10.84 (1H, s), 10.90 (1H, s).

5

10

15

20

25


30

35

40


Claims

1. A compound of formula (I):




wherein:

- R is methyl substituted by one to three groups selected from alkyl, aryl, alkenyl, and alkynyl;
 n is 0 or 1;
- 10 R¹ is arylmethyl or heterocyclylmethyl;
 R² is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and
 R³ is hydrogen, alkyl, alkenyl, alkynyl or aryl.
2. A compound according to claim 1, wherein R is allyl, propyl, ethyl or
 15 isopropyl, and/or R¹ is 1- or 2-naphthylmethyl; and/or R² is t-butyl; and/or R³ is hydrogen or methyl.
3. A compound according to claim 2, wherein each of n and R to R³ is
 20 selected from the group consisting of the values ascribed to it in the Examples hereinabove.
4. A compound according to claim 2, selected from the group consisting of the compounds described in the Examples hereinabove.
- 25 5. A compound according to claim 1 or 2, which is a compound of formula (IA):




6. The use of a compound according to any one of the preceding claims for the production of a medicament for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated.
7. A method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated, which method comprises the administration of a compound according to any one of claims 1 to 5 to a human or non-human mammal in need thereof.
8. A pharmaceutical composition for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated which comprises a compound according to any one of claims 1 to 5 and optionally a pharmaceutically acceptable carrier therefor.
9. The use of a compound according to any one of claims 1 to 5 for the production of a medicament for the treatment or prophylaxis of conditions mediated by TNF, including, but not limited to, inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.
10. A method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound according to any one of claims 1 to 5 to a human or non-human mammal in need thereof.
11. A process for preparing a compound according to any one of claims 1 to 5, which process comprises:
- (a) deprotecting a compound of formula (II):



wherein n and R to R³ are as defined hereinabove, and X is a protecting group such as benzyl or trimethylsilyl or

- 5 (b) reacting a compound of formula (III):



- wherein n and R to R³ are as defined hereinabove, and any hydroxy group is optionally protected, with hydroxylamine or a salt thereof, or
- 10 (c) converting a compound of formula (I) to a different compound of formula (I) as defined hereinabove.

12. A compound of formula (II) as defined in claim 11.
- 15 13. A compound of formula (III) as defined in claim 11.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01954

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C259/06 C07C237/22 A61K31/16 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 33165 A (BRITISH BIOTECH PHARM ;BECKETT RAYMOND PAUL (GB); MILLER ANDREW (G) 24 October 1996 (1996-10-24) abstract; claims 1,2,5-8,13,17 ---	1,5-13
X	WO 94 10990 A (GALLOWAY WILLIAM ALAN ;BRITISH BIO TECHNOLOGY (GB); CRIMMIN MICHAEL) 26 May 1994 (1994-05-26) page 3, paragraph 3 - page 9, line 22; claims 18-21 ---	1,5-10
P,X	WO 98 43959 A (BIRD THOMAS GEOFFREY COLERICK ;ZENECA PHARMA SA (FR); ZENECA LTD () 8 October 1998 (1998-10-08) page 9 - page 17; claims 1,7-10 ---	1,5-13
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 August 1999

Date of mailing of the international search report

30/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01954

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 02240 A (SMITHKLINE BEECHAM PLC ;CHRISTIE GARY (GB); WESTON BEVERLEY JANE () 1 February 1996 (1996-02-01) cited in the application the whole document ---	1,5-13
A	WO 97 02239 A (BRITISH BIOTECH PHARM ;HUXLEY PHILIP (GB); MARTIN FIONNA MITCHELL) 23 January 1997 (1997-01-23) cited in the application page 10 - page 16, paragraph 1 ---	1,5-13
A	WO 97 15553 A (SANKYO CO ;SHIBATA TOMOYUKI (JP); OHKAWA NOBUYUKI (JP); TAKEMOTO T) 1 May 1997 (1997-05-01) abstract; page 27, table 1; page 32, tabelle 2, compound 2-28 ---	1,5-13
A	WO 96 33166 A (DU PONT MERCK PHARMA) 24 October 1996 (1996-10-24) claims 1,5-13; tables 1,3 -----	1,5-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/01954

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7 AND 10
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7 AND 10
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01954

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9633165 A	24-10-1996	AU 5343696 A	07-11-1996
		EP 0821666 A	04-02-1998
		EP 0821668 A	04-02-1998
		WO 9633161 A	24-10-1996
		JP 11503746 T	30-03-1999
		JP 11503748 T	30-03-1999
		US 5840939 A	24-11-1998
		US 5908851 A	01-06-1999
WO 9410990 A	26-05-1994	AT 150300 T	15-04-1997
		AU 5430194 A	08-06-1994
		DE 69309094 D	24-04-1997
		DE 69309094 T	31-07-1997
		EP 0667770 A	23-08-1995
		ES 2101358 T	01-07-1997
		JP 8505605 T	18-06-1996
		US 5691382 A	25-11-1997
WO 9843959 A	08-10-1998	AU 6843298 A	22-10-1998
WO 9602240 A	01-02-1996	EP 0769939 A	02-05-1997
		JP 10502656 T	10-03-1998
WO 9702239 A	23-01-1997	AU 6311796 A	05-02-1997
		EP 0835240 A	15-04-1998
WO 9715553 A	01-05-1997	AU 7335496 A	15-05-1997
		JP 10081661 A	31-03-1998
WO 9633166 A	24-10-1996	US 5691381 A	25-11-1997
		AU 5556396 A	07-11-1996
		CA 2218380 A	24-10-1996
		EP 0821669 A	04-02-1997